This document discusses advances in stem cell therapy using dental stem cells. It summarizes that dental stem cells, such as dental pulp stem cells and stem cells from exfoliated deciduous teeth, have been shown to be a better source of mesenchymal stem cells than bone marrow. These dental stem cells can be isolated from accessible dental tissues, have high proliferative ability, and can differentiate into various cell types. Cryopreserved dental pulp tissues from exfoliated deciduous teeth are a feasible source of stem cells that maintain stem cell properties and have shown therapeutic potential for regenerative medicine applications and treating conditions like immune disorders.
Cultured skin substitutes prepared from cultured skin cells and biopolymers can reduce the need for donor skin grafts and have been shown to effectively treat excised burns, burn scars, and congenital skin lesions. Cultured skin substitutes generate skin phenotypes in the lab and restore tissue function and systemic homeostasis when implanted. Healed skin from cultured skin substitutes is smooth, soft and strong, though pigmentation may be irregular. Cultured skin substitutes close 67 times the area of donor skin compared to less than 4 times for split-thickness skin grafts, and result in similar qualitative outcomes.
Stem cells have potential applications in dentistry for tissue regeneration. There are several types of stem cells, including embryonic, adult, and induced pluripotent stem cells. Dental tissues contain stem cells that are advantageous for use due to high plasticity and ability to be cryopreserved. Current approaches to stem cell therapy include using stem cells from sources like bone marrow or dental pulp to regenerate bone or develop cell sheets. Research aims to regenerate whole teeth by transplanting bioengineered tooth units constructed from epithelial and mesenchymal stem cells into defects. These techniques could help with problems like root regeneration and prosthodontic treatments.
Stem cells found in dental tissues such as dental pulp, dental pulp of deciduous teeth, apical papilla, and dental follicle can differentiate into odontoblast cells and have potential applications in dental tissue regeneration and repair. There are several types of dental stem cells that can potentially be used to regenerate dental tissues and whole teeth. Delivery of growth factors has shown potential to induce homing of endogenous stem cells to regenerate dental pulp-like tissue in root canals of extracted human teeth implanted in mice without cell transplantation. Further research is still needed but dental stem cells show promise for applications in dental tissue engineering and whole tooth regeneration.
The Indian Dental Academy is the Leader in continuing dental education , training dentists in all aspects of dentistry and
offering a wide range of dental certified courses in different formats.
The Indian Dental Academy is the Leader in continuing dental education , training dentists in all aspects of dentistry and
offering a wide range of dental certified courses in different formats.
Denise Resen will give an informative speech on dental stem cells. She will discuss what dental stem cells are, the benefits they provide, how they are harvested and stored, and when this new technology will be available. Dental stem cells are unspecified cells harvested from extracted teeth that can be stored for future use in treating diseases and regenerating tissues. They are an accessible stem cell source and pose fewer ethical issues than other sources. Current technology allows for their storage in dental offices using collection kits.
STEM CELLS IN HUMAN EXFOLIATED DECIDUOUS TEETH(SHED)Upama Sishan
- Recent studies have shown that stem cells from human exfoliated deciduous teeth (SHED) can develop into more types of body tissue than other stem cell sources.
- SHED are a promising source of stem cells because they can be easily collected from discarded baby teeth, have a high proliferation rate, and may be useful for treating a variety of conditions through cell therapy and tissue regeneration.
- It is advantageous for parents to bank their child's SHED now while they are young and healthy to provide a guaranteed stem cell donor source for any future medical needs.
Autologous Mesenchymal Stem Cells in OrthopaedicsVladimir Bobic
Nuffield Health, The Grosvenor Hospital Chester, UK
27 June 2013. GP and Physiotherapy Seminar: Autologous Stem Cell Therapies in Orthopaedics. Moderator and Presenter: Vladimir Bobic, Chester Knee Clinic
Cultured skin substitutes prepared from cultured skin cells and biopolymers can reduce the need for donor skin grafts and have been shown to effectively treat excised burns, burn scars, and congenital skin lesions. Cultured skin substitutes generate skin phenotypes in the lab and restore tissue function and systemic homeostasis when implanted. Healed skin from cultured skin substitutes is smooth, soft and strong, though pigmentation may be irregular. Cultured skin substitutes close 67 times the area of donor skin compared to less than 4 times for split-thickness skin grafts, and result in similar qualitative outcomes.
Stem cells have potential applications in dentistry for tissue regeneration. There are several types of stem cells, including embryonic, adult, and induced pluripotent stem cells. Dental tissues contain stem cells that are advantageous for use due to high plasticity and ability to be cryopreserved. Current approaches to stem cell therapy include using stem cells from sources like bone marrow or dental pulp to regenerate bone or develop cell sheets. Research aims to regenerate whole teeth by transplanting bioengineered tooth units constructed from epithelial and mesenchymal stem cells into defects. These techniques could help with problems like root regeneration and prosthodontic treatments.
Stem cells found in dental tissues such as dental pulp, dental pulp of deciduous teeth, apical papilla, and dental follicle can differentiate into odontoblast cells and have potential applications in dental tissue regeneration and repair. There are several types of dental stem cells that can potentially be used to regenerate dental tissues and whole teeth. Delivery of growth factors has shown potential to induce homing of endogenous stem cells to regenerate dental pulp-like tissue in root canals of extracted human teeth implanted in mice without cell transplantation. Further research is still needed but dental stem cells show promise for applications in dental tissue engineering and whole tooth regeneration.
The Indian Dental Academy is the Leader in continuing dental education , training dentists in all aspects of dentistry and
offering a wide range of dental certified courses in different formats.
The Indian Dental Academy is the Leader in continuing dental education , training dentists in all aspects of dentistry and
offering a wide range of dental certified courses in different formats.
Denise Resen will give an informative speech on dental stem cells. She will discuss what dental stem cells are, the benefits they provide, how they are harvested and stored, and when this new technology will be available. Dental stem cells are unspecified cells harvested from extracted teeth that can be stored for future use in treating diseases and regenerating tissues. They are an accessible stem cell source and pose fewer ethical issues than other sources. Current technology allows for their storage in dental offices using collection kits.
STEM CELLS IN HUMAN EXFOLIATED DECIDUOUS TEETH(SHED)Upama Sishan
- Recent studies have shown that stem cells from human exfoliated deciduous teeth (SHED) can develop into more types of body tissue than other stem cell sources.
- SHED are a promising source of stem cells because they can be easily collected from discarded baby teeth, have a high proliferation rate, and may be useful for treating a variety of conditions through cell therapy and tissue regeneration.
- It is advantageous for parents to bank their child's SHED now while they are young and healthy to provide a guaranteed stem cell donor source for any future medical needs.
Autologous Mesenchymal Stem Cells in OrthopaedicsVladimir Bobic
Nuffield Health, The Grosvenor Hospital Chester, UK
27 June 2013. GP and Physiotherapy Seminar: Autologous Stem Cell Therapies in Orthopaedics. Moderator and Presenter: Vladimir Bobic, Chester Knee Clinic
Dental and orofacial mesenchymal stem cells in craniofacialAamir Godil
This document discusses dental and orofacial mesenchymal stem cells and their potential applications in craniofacial regeneration from the perspective of prosthodontists. It provides an overview of stem cell sources in dentistry, including dental tissue-derived stem cells like dental pulp stem cells, stem cells from exfoliated deciduous teeth, periodontal ligament stem cells, and gingival mesenchymal stem cells. It also discusses the use of hydrogels, particularly alginate hydrogel, as scaffolds for tissue engineering and encapsulating dental stem cells. Recent studies encapsulating dental stem cells in alginate hydrogels show promise for regenerating tissues like cartilage, tendon, and muscle.
Tissue Engineering in restorative dentistryLama K Banna
Stem cells have potential applications in regenerative dentistry. Dental stem cells can be isolated from sources like dental pulp, extracted teeth, and apical papilla. These stem cells may be used along with growth factors and scaffolds to regenerate tissues like dental pulp, dentin, cementum, and periodontal ligament. However, challenges remain such as a lack of available dental epithelial stem cells and scaling up the engineering of tooth structures. Further research is needed to address these obstacles and develop clinically feasible stem cell therapies for replacing lost tooth structures.
There are a lot of orthopedic conditions and injuries that presently have limited treatment options available.
Here regenerative technologies comes up as a ray of hope among surgeons for the treatment by functionally repairing the tissues and organs using growth factors, stem cells and products developed by genetic engineering with the advancement in the stem cells research field .
The purpose of this presentation is to first provide idea about the orthopedic conditions along with the therapeutic potential of stem cells to treat these diseases.
A Brief History of Regenerative MedicineJohn Makohen
In the presentation ISREGEN outlines the history of regenerative medicine fro it's earliest days when Robert Briggs and Thomas King began cloning frogs to the present medicinal advancements in stem cell research and repair.
Fundamental of mesenchymal stem cells as a promising candidate in regenerativ...Tee Huat
Mesenchymal stem cells (MSCs) are multipotent stromal cells that reside in connective tissues throughout the body. They are capable of differentiating into multiple mesenchymal lineages including bone, cartilage, and adipose tissues. MSCs also possess the ability to transdifferentiate into non-mesenchymal cell types. MSCs can migrate to sites of injury, inflammation, and tumors where they secrete soluble factors that can alter the tissue microenvironment. As such, MSCs show promise as a candidate for regenerative medicine applications given their differentiation potential and immunomodulatory properties.
This document summarizes stem cell research projects conducted by Dr. Mohammad Abbas at King Abdulaziz University. It outlines 5 research groups: 1) Isolation and characterization of bone marrow mesenchymal stem cells from osteoarthritis patients, 2) Effect of heat shock on bone marrow MSCs from OA patients, 3) Evaluation of ex-vivo cartilage regeneration using MSCs from OA patients, 4) Impact of MSCs impregnated with cartilage paste on repairing cartilage defects in rabbits, and 5) Impact of a hyaluronic acid scaffold impregnated with MSCs and cartilage paste on surgically induced arthritis in rabbits. Additional research includes studies on the effects of catecholamines and NSAIDs
Dr. Steenblock treats patients suffering from Macular Degeneration using Stem Cell Treatments. Contact his office today at 1-800-300-1063. Websites:
www.stemcellmd.org
www.strokedoctor.com
www.stemcelltherapies.org
www.cerebralpalsycure.com
www.davidsteenblock.com
www.davidsteenblock.net
A. B. C. of STEM CELL therapy Dr. Sharda jain Lifecare Centre StemcellGP21
This document provides information about LifeCare-ReeCure Centre, a stem cell therapy organization. It introduces the board of directors and discusses the sources of stem cells they use, such as bone marrow, menstrual blood, and hair follicles. It also outlines several diseases that can be treated with stem cell therapy according to the organization, including cardiovascular, neurological, liver, bone, and blood disorders. The document promotes the organization's proprietary technology and focus on treating "no hope" diseases. It shares case studies and testimonials of successful stem cell therapy treatments.
Tissue Engineering: A New Era in DentistryFatima A
Tissue engineering uses stem cells, scaffolds, and growth factors to regenerate dental and oral tissues as an alternative to implants. Stem cells are isolated from dental tissues and seeded onto a scaffold to provide a structure for new tissue to grow. Growth factors stimulate cell growth and differentiation. The developing tissue is grown in a bioreactor, which supports cell growth, before implantation. Tissue engineering could help address limitations of dental materials and implants by regenerating lost tissues rather than replacing them. Ethical issues around cell sources and who receives treatments require consideration. Researchers believe tissue engineering may one day enable completely engineered replacement teeth.
Human mesenchymal stem cell position within scaffold influences cell fate in ...Diana Santos
This document summarizes research on culturing human mesenchymal stem cells (hMSCs) using bioreactors to direct osteoblastic differentiation. Static culture limitations include non-uniform growth and nutrient diffusion constraints. Dynamic bioreactor culture using alginate beads overcomes these limitations. Studies show hMSC proliferation and osteoblastic markers like BMP-2 and OPN levels increase with shear stress levels and time in culture. hMSC position within scaffolds also influences fate, with inner regions of large beads showing higher differentiation. Dynamic culture thus enhances hMSC expansion and osteoblastic differentiation for applications like bone regeneration compared to static methods.
Cartilage Repair using Stem cell & OrthobiologicsVaibhav Bagaria
Regenerating Cartilage is a challenge. What's new in this field of cartilage regeneration and the current status of the stem cell use in this field is described.
Dental stem cells were discovered in 2000 and have since been studied extensively. They are found in dental pulp and other dental tissues. Dental stem cells can differentiate into several cell types including bone, connective tissue, muscle and neural cells. Research is exploring their potential to regenerate dental and craniofacial tissues through procedures like regenerative endodontics and periodontal regeneration. Dental stem cells may also help treat other conditions like heart disease, diabetes and neurological disorders. Further research is still needed but dental stem cells show promise for advancing regenerative dentistry and medicine.
Stem cells have the ability to become specialized cells and work with tissues and organs. There are two types: embryonic stem cells which come from embryos and can differentiate into any cell type, and adult stem cells which are more limited in what cells they can become. Stem cell therapy involves inserting stem cells into injured areas to produce new cells and has been used to treat conditions such as cerebral palsy, Parkinson's disease, and cancers. For spinal cord injuries, researchers are exploring therapies using bone marrow stem cells, cord blood cells, and other cell types which show promise in repairing damage in clinical trials.
What is Stem Cell ?
History of Stem Cells ?
Stages of Embryogenesis
Blastocyst Diagram
Three types of stem cells
Differentiation of ESC
Adult Stem Cells
Bone Marrow
Umbilical cord stem cells
Factors known to affect stem cells
Niche cells activates Stem cells
Regenerative Medicine : Indian Scenario
Stem cells are one of the important cells present in both plant and animals. these cells have ability to regenerate any part of the body work similarily as meristem cells in plant. The advances in the stem cell technology has open a new era in medical field. the advances in this technology has been presented here and their important application has been included in this present in this presentation.
Latest developments in stem cell therapy 2015CryoSave Arabia
The document discusses developments in stem cell therapy, noting that the number of hematopoietic stem cell transplants has increased 35% over 5 years to nearly 78,000 performed worldwide in 2014. Transplants using umbilical cord blood stem cells have also risen dramatically, from 11,000 in 2009 to over 30,000. Stem cells can be collected from bone marrow, umbilical cord blood, or peripheral blood and have been used since the 1950s to treat over 80 diseases including various cancers, blood disorders, and autoimmune conditions. The document encourages banking umbilical cord blood privately or donating it publicly given the potential future medical uses.
Learn about the possibilities of what Adult Stem Cell pose for the future of curing chronic disease, cancers, and how nutrition plays a part in their ability to keeping you healthy.
This document discusses the use of stem cells for dental tissue engineering. It outlines several types of dental stem cells that can be used, including dental pulp stem cells, stem cells from human exfoliated deciduous teeth, and periodontal ligament stem cells. These stem cells have applications in regenerating damaged dental tissues and inducing bone regeneration. Key elements of dental tissue engineering include scaffolds to support cell attachment and growth factor delivery, as well as the stem cells themselves. Dental stem cells show promise for developing new treatments for repairing damaged teeth and other dental tissues, but more research is still needed.
Stem cells in Dentistry | by Dr Alaa Al-saidiDenTeach
Dental pulp stem cells are derived from the dental pulp within teeth. They are multipotent stem cells that can differentiate into several cell types. Dental pulp stem cells are a promising source for regenerative dentistry and tissue engineering due to their accessibility and differentiation potential. They have applications in pulp regeneration, alveolar bone regeneration, and treatment of craniofacial defects. However, there are also challenges to their clinical use including low survival rates, contamination risks, and high costs.
Dental and orofacial mesenchymal stem cells in craniofacialAamir Godil
This document discusses dental and orofacial mesenchymal stem cells and their potential applications in craniofacial regeneration from the perspective of prosthodontists. It provides an overview of stem cell sources in dentistry, including dental tissue-derived stem cells like dental pulp stem cells, stem cells from exfoliated deciduous teeth, periodontal ligament stem cells, and gingival mesenchymal stem cells. It also discusses the use of hydrogels, particularly alginate hydrogel, as scaffolds for tissue engineering and encapsulating dental stem cells. Recent studies encapsulating dental stem cells in alginate hydrogels show promise for regenerating tissues like cartilage, tendon, and muscle.
Tissue Engineering in restorative dentistryLama K Banna
Stem cells have potential applications in regenerative dentistry. Dental stem cells can be isolated from sources like dental pulp, extracted teeth, and apical papilla. These stem cells may be used along with growth factors and scaffolds to regenerate tissues like dental pulp, dentin, cementum, and periodontal ligament. However, challenges remain such as a lack of available dental epithelial stem cells and scaling up the engineering of tooth structures. Further research is needed to address these obstacles and develop clinically feasible stem cell therapies for replacing lost tooth structures.
There are a lot of orthopedic conditions and injuries that presently have limited treatment options available.
Here regenerative technologies comes up as a ray of hope among surgeons for the treatment by functionally repairing the tissues and organs using growth factors, stem cells and products developed by genetic engineering with the advancement in the stem cells research field .
The purpose of this presentation is to first provide idea about the orthopedic conditions along with the therapeutic potential of stem cells to treat these diseases.
A Brief History of Regenerative MedicineJohn Makohen
In the presentation ISREGEN outlines the history of regenerative medicine fro it's earliest days when Robert Briggs and Thomas King began cloning frogs to the present medicinal advancements in stem cell research and repair.
Fundamental of mesenchymal stem cells as a promising candidate in regenerativ...Tee Huat
Mesenchymal stem cells (MSCs) are multipotent stromal cells that reside in connective tissues throughout the body. They are capable of differentiating into multiple mesenchymal lineages including bone, cartilage, and adipose tissues. MSCs also possess the ability to transdifferentiate into non-mesenchymal cell types. MSCs can migrate to sites of injury, inflammation, and tumors where they secrete soluble factors that can alter the tissue microenvironment. As such, MSCs show promise as a candidate for regenerative medicine applications given their differentiation potential and immunomodulatory properties.
This document summarizes stem cell research projects conducted by Dr. Mohammad Abbas at King Abdulaziz University. It outlines 5 research groups: 1) Isolation and characterization of bone marrow mesenchymal stem cells from osteoarthritis patients, 2) Effect of heat shock on bone marrow MSCs from OA patients, 3) Evaluation of ex-vivo cartilage regeneration using MSCs from OA patients, 4) Impact of MSCs impregnated with cartilage paste on repairing cartilage defects in rabbits, and 5) Impact of a hyaluronic acid scaffold impregnated with MSCs and cartilage paste on surgically induced arthritis in rabbits. Additional research includes studies on the effects of catecholamines and NSAIDs
Dr. Steenblock treats patients suffering from Macular Degeneration using Stem Cell Treatments. Contact his office today at 1-800-300-1063. Websites:
www.stemcellmd.org
www.strokedoctor.com
www.stemcelltherapies.org
www.cerebralpalsycure.com
www.davidsteenblock.com
www.davidsteenblock.net
A. B. C. of STEM CELL therapy Dr. Sharda jain Lifecare Centre StemcellGP21
This document provides information about LifeCare-ReeCure Centre, a stem cell therapy organization. It introduces the board of directors and discusses the sources of stem cells they use, such as bone marrow, menstrual blood, and hair follicles. It also outlines several diseases that can be treated with stem cell therapy according to the organization, including cardiovascular, neurological, liver, bone, and blood disorders. The document promotes the organization's proprietary technology and focus on treating "no hope" diseases. It shares case studies and testimonials of successful stem cell therapy treatments.
Tissue Engineering: A New Era in DentistryFatima A
Tissue engineering uses stem cells, scaffolds, and growth factors to regenerate dental and oral tissues as an alternative to implants. Stem cells are isolated from dental tissues and seeded onto a scaffold to provide a structure for new tissue to grow. Growth factors stimulate cell growth and differentiation. The developing tissue is grown in a bioreactor, which supports cell growth, before implantation. Tissue engineering could help address limitations of dental materials and implants by regenerating lost tissues rather than replacing them. Ethical issues around cell sources and who receives treatments require consideration. Researchers believe tissue engineering may one day enable completely engineered replacement teeth.
Human mesenchymal stem cell position within scaffold influences cell fate in ...Diana Santos
This document summarizes research on culturing human mesenchymal stem cells (hMSCs) using bioreactors to direct osteoblastic differentiation. Static culture limitations include non-uniform growth and nutrient diffusion constraints. Dynamic bioreactor culture using alginate beads overcomes these limitations. Studies show hMSC proliferation and osteoblastic markers like BMP-2 and OPN levels increase with shear stress levels and time in culture. hMSC position within scaffolds also influences fate, with inner regions of large beads showing higher differentiation. Dynamic culture thus enhances hMSC expansion and osteoblastic differentiation for applications like bone regeneration compared to static methods.
Cartilage Repair using Stem cell & OrthobiologicsVaibhav Bagaria
Regenerating Cartilage is a challenge. What's new in this field of cartilage regeneration and the current status of the stem cell use in this field is described.
Dental stem cells were discovered in 2000 and have since been studied extensively. They are found in dental pulp and other dental tissues. Dental stem cells can differentiate into several cell types including bone, connective tissue, muscle and neural cells. Research is exploring their potential to regenerate dental and craniofacial tissues through procedures like regenerative endodontics and periodontal regeneration. Dental stem cells may also help treat other conditions like heart disease, diabetes and neurological disorders. Further research is still needed but dental stem cells show promise for advancing regenerative dentistry and medicine.
Stem cells have the ability to become specialized cells and work with tissues and organs. There are two types: embryonic stem cells which come from embryos and can differentiate into any cell type, and adult stem cells which are more limited in what cells they can become. Stem cell therapy involves inserting stem cells into injured areas to produce new cells and has been used to treat conditions such as cerebral palsy, Parkinson's disease, and cancers. For spinal cord injuries, researchers are exploring therapies using bone marrow stem cells, cord blood cells, and other cell types which show promise in repairing damage in clinical trials.
What is Stem Cell ?
History of Stem Cells ?
Stages of Embryogenesis
Blastocyst Diagram
Three types of stem cells
Differentiation of ESC
Adult Stem Cells
Bone Marrow
Umbilical cord stem cells
Factors known to affect stem cells
Niche cells activates Stem cells
Regenerative Medicine : Indian Scenario
Stem cells are one of the important cells present in both plant and animals. these cells have ability to regenerate any part of the body work similarily as meristem cells in plant. The advances in the stem cell technology has open a new era in medical field. the advances in this technology has been presented here and their important application has been included in this present in this presentation.
Latest developments in stem cell therapy 2015CryoSave Arabia
The document discusses developments in stem cell therapy, noting that the number of hematopoietic stem cell transplants has increased 35% over 5 years to nearly 78,000 performed worldwide in 2014. Transplants using umbilical cord blood stem cells have also risen dramatically, from 11,000 in 2009 to over 30,000. Stem cells can be collected from bone marrow, umbilical cord blood, or peripheral blood and have been used since the 1950s to treat over 80 diseases including various cancers, blood disorders, and autoimmune conditions. The document encourages banking umbilical cord blood privately or donating it publicly given the potential future medical uses.
Learn about the possibilities of what Adult Stem Cell pose for the future of curing chronic disease, cancers, and how nutrition plays a part in their ability to keeping you healthy.
This document discusses the use of stem cells for dental tissue engineering. It outlines several types of dental stem cells that can be used, including dental pulp stem cells, stem cells from human exfoliated deciduous teeth, and periodontal ligament stem cells. These stem cells have applications in regenerating damaged dental tissues and inducing bone regeneration. Key elements of dental tissue engineering include scaffolds to support cell attachment and growth factor delivery, as well as the stem cells themselves. Dental stem cells show promise for developing new treatments for repairing damaged teeth and other dental tissues, but more research is still needed.
Stem cells in Dentistry | by Dr Alaa Al-saidiDenTeach
Dental pulp stem cells are derived from the dental pulp within teeth. They are multipotent stem cells that can differentiate into several cell types. Dental pulp stem cells are a promising source for regenerative dentistry and tissue engineering due to their accessibility and differentiation potential. They have applications in pulp regeneration, alveolar bone regeneration, and treatment of craniofacial defects. However, there are also challenges to their clinical use including low survival rates, contamination risks, and high costs.
This document discusses hematopoietic stem cell transplantation (HSCT) and its current state and future opportunities. HSCT is an effective treatment for hematologic, immune, metabolic and cancerous diseases. It replaces defective cells and offers high-dose therapy and graft-versus-tumor effects. While HSCT faces challenges like toxicity and costs, advances in unrelated donor matching, cord blood use, and reduced intensity regimens have expanded its applications. Standards and accreditation are needed to ensure quality, and further growth depends on expanded donor availability and combining HSCT with new cellular immunotherapies.
Síguenos en Facebook
Consultoría de Recursos Humanos y Marketing.
Advantia Consultores
www.advantiaconsultores.es
www.facebook.com/advantiaconsultores info@advantiaconsultores.es
Este documento presenta el currículum de Adrián Aragonés García, un cineasta y artista español. Detalla su experiencia en la dirección de cortometrajes, documentales y videos musicales. También incluye su experiencia como ayudante de dirección, editor, ejecutivo de cuentas de publicidad y periodista. Por último, proporciona información sobre su educación, que incluye una licenciatura en Bellas Artes y un máster en Realización de Cine y Televisión.
The Employers' Association PowerPoint PresentationSarah Beddoes
The Employers' Association (EA) provides human resources solutions, professional training, and wellness consulting services to local companies. Formed over 60 years ago by local companies, the EA serves over 600 member organizations across various industries. Members benefit from HR support, surveys, newsletters, training seminars, and on-site consulting. The presentation emphasizes the EA's expertise in helping busy employers stay compliant and empowering excellence through learning and wellness opportunities.
Advances in stem cell therapies in the treatment of MSMS Trust
This document summarizes advances in stem cell therapies for the treatment of multiple sclerosis (MS). It discusses several approaches:
1) Transplantation of oligodendrocyte precursor cells, which may not be effective due to the presence of endogenous precursors in MS lesions.
2) Hematopoietic stem cell transplantation, which reduces relapses in 80-85% of cases but has no proven effect on progression and risks of 1.3-5% mortality.
3) Mesenchymal stem cells and bone marrow mononuclear cells, which may aid repair through immunomodulation and other mechanisms rather than direct cell replacement.
Fully automatic anti collision train signalling projectHina Saxena
This document is a project report submitted by four students for their Bachelor of Technology degree. It outlines their work on developing a fully automatic anti-collision system for train signalling. The system is designed to control railway tracks using sensors and a microcontroller to avoid accidents. It places sensors at distances from gates to detect approaching trains and control gate operations. Indicator lights also alert motorists of oncoming trains. Diagrams and descriptions of the working model are provided, which uses sensors to detect trains and automatically switch tracks or control gates to prevent collisions. Devices used in the system like the microcontroller, sensors, displays and other electronics are described.
The use of stem cells in office procedures as the practice of medicine is commercializing in the USA, there are risks that arise because of this, but there are also benefits that are possible. Regulation is needed, but barring an MD and its patient from these procedures simply pushes them outside of the country or into incognito modes. This is where true danger arises, a path to expeditiously and ethically practice should be established where the patient consent is true, and the doctor is enhanced in his practice rather than tied down.
Stem cell therapy holds promise for treating many incurable diseases by replacing damaged cells. There are various types of stem cells including embryonic, adult, and induced pluripotent stem cells. While embryonic stem cells can differentiate into any cell type, their use is controversial due to requiring embryo destruction. Alternative sources like adult stem cells and iPS cells do not have the same ethical issues but may have limitations. Stem cell research faces challenges like preventing immune rejection and tumor formation but continues to advance regenerative medicine.
A stem cell is a "blank" cell that can give rise to multiple tissue types such as a skin, muscle, or nerve cell.
Under certain physiologic or experimental conditions, they can be induced to become tissue- or organ-specific cells with special functions.
Las células stem son células no diferenciadas con capacidad de proliferación, autorrenovación y producción de células diferenciadas. Pueden regenerar tejidos después de una lesión y tienen flexibilidad para diferenciarse en diferentes tipos celulares. Existen células stem embrionarias y adultas con distintos grados de potencial de diferenciación.
El documento describe la composición de los manuales de usuario y técnico. El manual de usuario instruye al usuario sobre el uso del sistema y la solución de problemas, e incluye una introducción, objetivos, guía de uso, solución de problemas y contactos de soporte. El manual técnico está dirigido al equipo de TI y desarrolladores e incluye objetivos, normas, descripción de bases de datos, diseño de reportes y pantallas.
Stem cells are undifferentiated cells that can differentiate into specialized cells and can self-renew. There are several types of stem cells including embryonic, adult, and fetal stem cells. Embryonic stem cells are the most versatile but also raise ethical issues, while adult stem cells are more limited in their differentiation potential. Stem cell therapy works by stem cells differentiating into the type of cells needed to repair damaged tissue when transplanted into the body. Current applications of stem cell therapy include treating diseases like cancer, diabetes, and Parkinson's disease.
El documento resume un encuentro sobre prensa popular que tuvo lugar en tres grandes ciudades: Bogotá, Buenos Aires y Salvador de Bahía. Cada ciudad tiene un nuevo periódico popular dirigido a las masas que no son alcanzadas por la prensa tradicional. El desafío es crear publicaciones que se sientan cercanas a sus lectores en cada lugar.
Here are a few key points I gathered from our discussion:
- It's important to talk to potential customers, partners, experts to get feedback and guidance at an early stage. Their perspectives will help shape your strategy.
- Every customer/partner will have unique needs, so understand each one individually rather than assuming one size fits all.
- Conferences are a great way to efficiently network, learn from others, and promote your ideas.
- Experts in the field can provide reality checks on your hypotheses, plans and give advice based on their experience.
- An MVP is crucial to demonstrate proof of concept and de-risk the technology before seeking major investments.
- Affordability for patients is a
This document provides a literature review on bio-fuel production from green solid waste via pyrolysis. It discusses biomass sources like forestry and agricultural residues. Pyrolysis is introduced as a thermo-chemical process to convert biomass into solid, liquid, and gas products without oxygen. Fast pyrolysis is highlighted as the preferred method to produce bio-oil, yielding 60-75% liquid, 15-25% char, and 10-20% gas. Characteristics of pyrolysis oil and its applications are also summarized.
Especial av. mackenzie correio popular - junho 2015THCM
A União Europeia está preocupada com o impacto ambiental do plástico descartável e planeja proibir itens como canudos, talheres e pratos de plástico até 2021 para reduzir os resíduos plásticos nos oceanos. A proibição afetará produtos de plástico de único uso que são comumente encontrados nas praias e águas da UE. Espera-se que a medida ajude a prevenir danos à vida marinha e à cadeia alimentar.
Artículos Científicos - Células Madre Dentales - BioEDEN MexicoBioEDEN Mexico
The document summarizes several scientific articles about the therapeutic potential of dental stem cells. It discusses how dental stem cells from teeth, both primary and permanent, can be extracted and multiplied in vitro to generate trillions of cells for therapeutic use. These stem cells are multipotent and can differentiate into various cell types like nerve cells, adipocytes, osteoblasts, chondrocytes, myocytes and odontoblasts. Due to their accessibility and high proliferation rates, dental stem cells are good candidates for tissue engineering and regenerative treatments. The document provides summaries of specific articles about using dental stem cells for conditions like skin regeneration, bone and craniofacial structure regeneration, cardiac regeneration, neurological problems, corneal regeneration and others
Articulos cientificos celulas madre dentales nuevoBioEDEN Mexico
The document discusses the potential therapeutic uses of stem cells derived from dental tissues. It provides an overview of several scientific articles on this topic, which found that dental stem cells can differentiate into various cell types, including nerve cells, adipocytes, osteoblasts, chondrocytes, myocytes and odontoblasts. The stem cells may be useful for dental tissue regeneration, bone and craniofacial structure regeneration, cardiac regeneration, neurological problems, corneal regeneration, skin regeneration, diabetes treatment, and hepatic regeneration among other applications. The document provides links to read full articles on stem cells from dental tissues and their potential to treat various medical conditions.
This document discusses stem cells and their role in operative dentistry and endodontics. It defines tissue engineering as using stem cells, growth factors, and scaffolds to develop biological substitutes. Regenerative endodontics aims to physiologically replace damaged tooth structures. Stem cells are undifferentiated cells that can self-renew and differentiate. Dental stem cells like dental pulp stem cells, stem cells from exfoliated deciduous teeth, stem cells from the apical papilla, and periodontal ligament stem cells show potential for regenerative applications like periodontal regeneration, bone regeneration, and salivary gland regeneration. Challenges to further development include controlling tooth size, root formation, and eruption for bio-tooth
Stem cells have the ability to reproduce and differentiate into specialized cells. The document discusses various types of stem cells including embryonic, adult, dental, and induced pluripotent stem cells. It provides details on stem cell sources from oral and maxillofacial regions like dental pulp stem cells, stem cells from exfoliated deciduous teeth, and periodontal ligament stem cells. The document concludes that stem cell-based therapies show potential for repairing and regenerating tissues and that continued research may enable whole tooth regeneration.
Tooth bioengineering and the next generation of dentistryAmir Rajaey
Tooth bioengineering and the next generation of dentistry.
As a result of numerous rapid and exciting developments in tissue engineering technology, scientists are able to regenerate a fully functional tooth in animal models, from a bioengineered tooth germ. Advances in technology, together with our understanding of the mechanisms of tooth development and studies dealing with dentally derived stem cells, have led to significant progress in the field of tooth regeneration
This document provides an overview of regenerative endodontics, which aims to regenerate dental tissues through biologically-based procedures using stem cells, growth factors, and scaffolds. Key elements for pulp regeneration include reliable stem cell sources, such as dental pulp stem cells, growth factors to stimulate cell proliferation and differentiation, and appropriate scaffolds. Potential regenerative therapies include revascularization, stem cell therapy, scaffold implantation, and gene delivery. Measuring clinical outcomes and further applications are areas of future focus to develop regenerative endodontic therapies.
International Journal of Pharmaceutical Science Invention (IJPSI)inventionjournals
International Journal of Pharmaceutical Science Invention (IJPSI) is an international journal intended for professionals and researchers in all fields of Pahrmaceutical Science. IJPSI publishes research articles and reviews within the whole field Pharmacy and Pharmaceutical Science, new teaching methods, assessment, validation and the impact of new technologies and it will continue to provide information on the latest trends and developments in this ever-expanding subject. The publications of papers are selected through double peer reviewed to ensure originality, relevance, and readability. The articles published in our journal can be accessed online
This study extracted mesenchymal stem cells from dental pulp tissue from a freshly extracted deciduous tooth. The cells were cultured and showed active growth over 35 days. Chromosome analysis of 25 and 100 cells at 20 and 35 days found no abnormalities. This establishes a method for extracting and culturing stem cells from deciduous teeth, a biological waste, for potential therapeutic applications. Further research with more samples and passage cultures is needed to validate producing these stem cells at larger scales.
This document discusses regenerative endodontics and the potential for dental pulp stem cells to regenerate damaged dentin and pulp tissues. It describes how dental pulp stem cells can proliferate and differentiate into odontoblasts and other cell types, potentially regenerating the dentin-pulp complex. Studies with dental pulp stem cells in scaffolds and with growth factors have shown new dentin formation in animal models, raising the possibility of clinical treatments to repair teeth and prevent tooth loss. The document reviews the key components needed for regenerative endodontics, including appropriate stem cells, scaffolds, and growth factors.
This document provides an introduction to regenerative endodontics, which aims to replace damaged dental structures through biological procedures rather than traditional root canal treatments. It defines key concepts like regeneration versus repair and discusses the history and components of regenerative endodontics. Specifically, it outlines sources of stem cells in the dental pulp, papilla, and periapical tissues that can be recruited to sites of injury and differentiated to produce new tissues. Growth factors and scaffolds provide signaling and structure to guide the stem cells in regeneration. The ultimate goals are to eliminate symptoms, enhance bone healing, and potentially increase root length, though complete regeneration of the original pulp-dentine complex is difficult to achieve.
This document provides an overview of regenerative endodontics, which aims to regenerate dental tissues through biological procedures. The key elements required are stem cells, growth factors, and scaffolds. Stem cells that may be suitable include dental pulp stem cells, stem cells from exfoliated deciduous teeth, and stem cells of the apical papilla. Regenerative endodontic procedures seek to regenerate pulp-like tissues and stimulate further root development, offering improved outcomes over current treatments. Additional research is needed to develop these techniques for clinical use in regenerating damaged dental tissues.
Stem cells have potential for regeneration in dentistry. Dental stem cells can be isolated from tissues like pulp, periodontal ligament, and follicle. These stem cells demonstrate self-renewal and differentiation abilities. Studies show dental stem cells can generate dentin, bone, and whole tooth crowns. Periodontal regeneration utilizes stem cells which differentiate into fibroblasts, cementoblasts, and osteoblasts to form periodontal tissues. Specifically, periodontal ligament stem cells implanted into defects have generated cementum, bone, and ligament regeneration.
Mix powders together in 1:1:1 ratio.
Add small amount of carrier (MP) and mix to a thick paste consistency.
Add remaining carrier and mix thoroughly.
Store in sealed container at room temperature.
Use within 1 month.
6/1/2017 39
Placement of intracanal medicament
Antibiotic paste is placed into the canal with a hand plugger or
lentulo spiral to the full working length.
Excess paste is removed from the canal orifice with a small
paper point.
Temporary restoration is placed.
Medicament is left in place for 1-
The document discusses regenerative endodontics, which aims to replace damaged tooth structures through biologically-based procedures. The key elements of regeneration are stem cells, growth factors, and scaffolds. Various stem cell types found in dental and other tissues are reviewed. Growth factors that promote stem cell differentiation are also discussed. The document provides details on the clinical protocol for regenerative endodontic therapy.
This document summarizes a review article on regenerative endodontics using the cell homing technique. It provides an overview of the cell homing technique, which involves regeneration through chemotaxis of endogenous stem cells to the injury site. The document then reviews 9 clinical trials on regenerative endodontics using cell homing. The results show promise for immature teeth but are contradictory for mature teeth. Regenerative endodontics aims to regenerate damaged pulp tissues to preserve tooth vitality and sensitivity while avoiding necrosis.
A detailed description of regenerative endodontics with illustrated journals right from its history,, needs, till its future advancements and challenges...
Regenerative endodontic procedures are designed to replace damaged structures, including dentin and root structures, as well as cells of the pulp-dentin complex
"Tissue Engineering": Competition Experience ReportFatima A
A brief report regarding our poster presentation, given to faculty and peers at a professional development conference in the college after the IADSR event.
Regenerative endodontics aims to regenerate damaged pulp and root structures through biologically-based procedures. Historically, studies in the 1960s-70s showed blood clots could induce tissue formation in root canals. Current methods include placing stem cells on scaffolds with growth factors in the root canal to regenerate the pulp-dentin complex. Triple antibiotic paste, calcium hydroxide, and MTA are used as antimicrobial medicaments. The protocol involves inducing bleeding into the root canal to form a blood clot which triggers regeneration. The goal is periradicular health and evidence of vital regenerated tissue through radiographic and clinical measures.
Osseo-integrated dental implants have been widely used for the rehabilitation of tooth loss. Although dental implants
are considered an available treatment in the paradigm shift from traditional dental therapies, such as fixed dental bridges and
removable dentures, the fundamental problems must be overcome prior to their clinical use in young patients who are still
undergoing jawbone growth. A bio-engineered functional bio-hybrid implant that is combined with adult-derived periodontal
tissue and attached with bone tissue can act as a substitute for cementum. This bio-hybrid implant was successfully engrafted
and it restored physiological function, including bone remodelling, regeneration and appropriate responsiveness to noxious
stimuli. Thus, this article reviews the functional bio-hybrid implant’s potential for clinical use as a next-generation dental
implant using adult-derived tissues.
A senior police officer in Chennai filed a complaint alleging that his phone calls were being illegally monitored by intelligence officials. An investigation was launched into the complaint. Senior police officials said only the call records of the officer's driver were screened as part of a probe into allegations that the driver had misused a police vehicle for a long period. The intelligence department said they were looking into complaints that the vehicle was captured on CCTV cameras at a toll plaza many times in recent months. The officer who made the complaint felt his phone was being surveilled but senior police said there was no evidence of this and he may have misunderstood the situation.
Stemade, a technology startup, has launched a new Dual Storage facility. The facility allows customers to store their data both locally and in the cloud for redundancy. This provides an affordable way for businesses and individuals to back up their important files and ensure data is not lost.
Emotional and Behavioural Problems in Children - Counselling and Family Thera...PsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
2024 Media Preferences of Older Adults: Consumer Survey and Marketing Implica...Media Logic
When it comes to creating marketing strategies that target older adults, it is crucial to have insight into their media habits and preferences. Understanding how older adults consume and use media is key to creating acquisition and retention strategies. We recently conducted our seventh annual survey to gain insight into the media preferences of older adults in 2024. Here are the survey responses and marketing implications that stood out to us.
Digital Health in India_Health Informatics Trained Manpower _DrDevTaneja_15.0...DrDevTaneja1
Digital India will need a big trained army of Health Informatics educated & trained manpower in India.
Presently, generalist IT manpower does most of the work in the healthcare industry in India. Academic Health Informatics education is not readily available at school & health university level or IT education institutions in India.
We look into the evolution of health informatics and its applications in the healthcare industry.
HIMMS TIGER resources are available to assist Health Informatics education.
Indian Health universities, IT Education institutions, and the healthcare industry must proactively collaborate to start health informatics courses on a big scale. An advocacy push from various stakeholders is also needed for this goal.
Health informatics has huge employment potential and provides a big business opportunity for the healthcare industry. A big pool of trained health informatics manpower can lead to product & service innovations on a global scale in India.
At Malayali Kerala Spa Ajman we providing the top quality massage services for our customers.
Our massage center prioritizes efficiency to ensure a quality massage experience for our clients at Malayali Kerala Spa Ajman. We offer a convenient appointment system and precise massage services.
Reach us at Villa No 7, Near Ammar Bin Yasir Street Al Rashidiya 2 - Ajman - United Arab Emirates.
Phone : +971 529818279
The Ultimate Guide in Setting Up Market Research System in Health-TechGokul Rangarajan
How to effectively start market research in the health tech industry by defining objectives, crafting problem statements, selecting methods, identifying data collection sources, and setting clear timelines. This guide covers all the preliminary steps needed to lay a strong foundation for your research.
"Market Research it too text-booky, I am in the market for a decade, I am living research book" this is what the founder I met on the event claimed, few of my colleagues rolled their eyes. Its true that one cannot over look the real life experience, but one cannot out beat structured gold mine of market research.
Many 0 to 1 startup founders often overlook market research, but this critical step can make or break a venture, especially in health tech.
But Why do they skip it?
Limited resources—time, money, and manpower—are common culprits.
"In fact, a survey by CB Insights found that 42% of startups fail due to no market need, which is like building a spaceship to Mars only to realise you forgot the fuel."
Sudharsan Srinivasan
Operational Partner Pitchworks VC Studio
Overconfidence in their product’s success leads founders to assume it will naturally find its market, especially in health tech where patient needs, entire system issues and regulatory requirements are as complex as trying to perform brain surgery with a butter knife. Additionally, the pressure to launch quickly and the belief in their own intuition further contribute to this oversight. Yet, thorough market research in health tech could be the key to transforming a startup's vision into a life-saving reality, instead of a medical mishap waiting to happen.
Example of Market Research working
Innovaccer, founded by Abhinav Shashank in 2014, focuses on improving healthcare delivery through data-driven insights and interoperability solutions. Before launching their platform, Innovaccer conducted extensive market research to understand the challenges faced by healthcare organizations and the potential for innovation in healthcare IT.
Identifying Pain Points: Innovaccer surveyed healthcare providers to understand their difficulties with data integration, care coordination, and patient engagement. They found widespread frustration with siloed systems and inefficient workflows.
Competitive Analysis: Analyzed competitors offering similar solutions in healthcare analytics and interoperability. Identified gaps in comprehensive data aggregation, real-time analytics, and actionable insights.
Regulatory Compliance: Ensured their platform complied with HIPAA and other healthcare data privacy regulations. This compliance was crucial to gaining trust from healthcare providers wary of data security issues.
Customer Validation: Conducted pilot programs with several healthcare organizations to validate the platform's effectiveness in improving care outcomes and operational efficiency. Gathered feedback to refine features and user interface.
Research, Monitoring and Evaluation, in Public Healthaghedogodday
This is a presentation on the overview of the role of monitoring and evaluation in public health. It describes the various components and how a robust M&E system can possitively impact the results or effectiveness of a public health intervention.
Sectional dentures for microstomia patients.pptxSatvikaPrasad
Microstomia, characterized by an abnormally small oral aperture, presents significant challenges in prosthodontic treatment, including limited access for examination, difficulties in impression making, and challenges with prosthesis insertion and removal. To manage these issues, customized impression techniques using sectional trays and elastomeric materials are employed. Prostheses may be designed in segments or with flexible materials to facilitate handling. Minimally invasive procedures and the use of digital technologies can enhance patient comfort. Education and training for patients on prosthesis care and maintenance are crucial for compliance. Regular follow-up and a multidisciplinary approach, involving collaboration with other specialists, ensure comprehensive care and improved quality of life for microstomia patients.
This particular slides consist of- what is hypotension,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is the summary of hypotension:
Hypotension, or low blood pressure, is when the pressure of blood circulating in the body is lower than normal or expected. It's only a problem if it negatively impacts the body and causes symptoms. Normal blood pressure is usually between 90/60 mmHg and 120/80 mmHg, but pressures below 90/60 are generally considered hypotensive.
Cyclothymia Test: Diagnosing, Symptoms, Treatment, and Impact | The Lifescien...The Lifesciences Magazine
The cyclothymia test is a pivotal tool in the diagnostic process. It helps clinicians assess the presence and severity of symptoms associated with cyclothymia.
VEDANTA AIR AMBULANCE SERVICES IN REWA AT A COST-EFFECTIVE PRICE.pdfVedanta A
Air Ambulance Services In Rewa works in close coordination with ground-based emergency services, including local Emergency Medical Services, fire departments, and law enforcement agencies.
More@: https://tinyurl.com/2shrryhx
More@: https://tinyurl.com/5n8h3wp8
NURSING MANAGEMENT OF PATIENT WITH EMPHYSEMA .PPTblessyjannu21
Prepared by Prof. BLESSY THOMAS, VICE PRINCIPAL, FNCON, SPN.
Emphysema is a disease condition of respiratory system.
Emphysema is an abnormal permanent enlargement of the air spaces distal to terminal bronchioles, accompanied by destruction of their walls and without obvious fibrosis.
Emphysema of lung is defined as hyper inflation of the lung ais spaces due to obstruction of non respiratory bronchioles as due to loss of elasticity of alveoli.
It is a type of chronic obstructive
pulmonary disease.
It is a progressive disease of lungs.
Satisfying Spa Massage Experience at Just 99 AED - Malayali Kerala Spa AjmanMalayali Kerala Spa Ajman
Our Spa Massage Center Ajman prioritizes efficiency to ensure a satisfying massage experience for our clients at Malayali Kerala Spa Ajman. We offer a hassle-free appointment system, effective health issue identification, and precise massage techniques.
Our Spa in Ajman stands out for its effectiveness in enhancing wellness. Our therapists focus on treating the root cause of issues, providing tailored treatments for each client. We take pride in offering the most satisfying Pakistani Spa service, adjusting treatment plans based on client feedback.
For the most result-oriented Russian Spa treatment in Ajman, visit our Massage Center. Our Russian therapists are skilled in various techniques to address health concerns. Our body-to-body massage is efficient due to individualized care and high-grade massage oils.
2. 02
Index
Dental Stem Cells Compared to Bone Marrow . . . . . . . .
Dental Stem Cells as a source . . . . . . . .
Dental Stem Cells for tooth /Organ regeneration . . . . . . . .
Dental Stem Cells for Bone regeneration . . . . . . . .
Stem Cells used for Sinus Augmentation . . . . . . . .
Stem Cells for Orthopaedic Applications . . . . . . . .
Stem Cells in Opthalmic Applications . . . . . . . .
Stem Cells in Cardiac Applications . . . . . . . .
Stem Cells used for Diabetes Treatment . . . . . . . .
Neurological applications of Stem Cells . . . . . . . .
Immuno-modulatory properties of Stem Cells used in Therapy . . . . . . . .
Stem cells used to treat Liver conditions . . . . . . . .
03
04
05
06
07
08
10
13
16
19
21
23
3. 03
DentalStemCellsproventobeabettersourceof
Mesenchymalstemcellsthanbonemarrow
Mesenchymal Stem Cells Derived from Dental Tissues vs. Those from Other
Sources: Their Biology and Role in Regenerative Medicine
CRITICAL REVIEWS IN ORAL Biology & Medicine
G.T.-J. Huang1*, S. Gronthos2, and S. Shi3
Abstract
To date, 5 different human dental stem/progenitor cells have been isolated and characterized: dental pulp
stem cells (DPSCs), stem cells from exfoliated deciduous teeth (SHED), periodontal ligament stem cells
(PDLSCs), stem cells from apical papilla (SCAP), and dental follicle progenitor cells (DFPCs). These post-
natal populations have mesenchymal- stem-cell-like (MSC) qualities, including the capacity for self-renewal
and multilineage differentiation potential. MSCs derived from bone marrow (BMMSCs) are capable of giving
rise to various lineages of cells, such as osteogenic, chondrogenic,adipogenic, myogenic, and neurogenic
cells. The dental-tissue-derived stem cells are isolated from specialized tissue with potent capacitiesto
differentiate into odontogenic cells. However,they also have the ability to give rise to other cell lineages similar
to, but different in potency from,that of BMMSCs. This article will review the isolation and characterization of
the properties of different dental MSC-like populations in comparison with those of other MSCs, such as
BMMSCs. Important issues in stem cell biology, such as stem cell niche, homing, and immunoregulation, will
also be discussed.
1University of Maryland, College of Dental Surgery, Dental School, Department of Endodontics, Prosthodontics and Operative
Dentistry, 650 West Baltimore St., Baltimore, MD 21201, USA;
2Mesenchymal Stem Cell Group, Division of Haematology, Institute of Medical and Veterinary Science, Adelaide 5000, South
Australia, Australia; and 3Center for Craniofacial Molecular Biology, University of Southern California School of Dentistry, Los
Angeles, CA90033, USA; *corresponding author,ghuang@umaryland.edu J Dent Res 88(9):792-806, 2009
1
SHED: Stem cells from human exfoliated deciduous teeth
To isolate high-quality human postnatal stem cells from accessible resources is an important goal for stem-
cell research. In this study we found that exfoliated human deciduous tooth contains multi-potent stem cells
[stem cells from human exfoliated deciduous teeth (SHED)]. SHED were identified to be a population of
highlyproliferative, clonogenic cells capable of differentiating into a variety of cell types including neural cells,
adipocytes, and odon-toblasts. After in vivo transplantation, SHED were found to be able to induce bone
formation, generate dentin, and survive in mouse brain along with expression of neural markers. Here we
show that a naturally exfoliated human organ contains a population of stemcells that are completely different
from previously identified stem cells. SHED are not only derived from a very accessible tissue resource but
are also capable of providing enough cells for poten- tial clinical application. Thus, exfoliated teeth may be an
unexpected unique resource for stem-cell therapies including autologous stem-cell transplantation and
tissue engineering.
www.pnas.orgycgiydoiy10.1073ypnas.0937635100 PNAS u May 13, 2003 u vol. 100 u no. 10 u 5807–5812
Masako Miura*, Stan Gronthos†, Mingrui Zhao‡, Bai Lu‡, Larry W. Fisher*, Pamela Gehron Robey*, and Songtao Shi*§
*Craniofacial and Skeletal Diseases Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health,
Bethesda, MD 20892; †Mesenchymal Stem Cell Group, Division of Haematology, Institute of Medical and Veterinary Science, Frome
Road, Adelaide 5000, South Australia, Australia; and ‡Section on Neural Development and Plasticity, National Institute of Child Health
and Human Development, National Institutes of Health, Bethesda, MD 20892 Edited by Anthony P. Mahowald, University of Chicago,
Chicago, IL, and approved March 12, 2003 (received for review December 16, 2002)
4. Stem cell (SC) therapy has a promising future for tissue regenerative medicine. However, because SC technology
is still in its infancy, interdisciplinary cooperation is needed to achieve successful clinical applications. Dental SCs
have drawn attention in recent years because of their accessibility, plasticity, and high proliferative ability. Several
types of dental SCs have been identified, including dental pulp SCs from adult human dental pulp, SCs from
human primary exfoliated deciduous teeth, periodontal ligament SCs, and dental follicle SCs from human third
molars. Similar to mesenchymal SCs, these dental SCs can undergo self-renewal and have multipotent
differentiation ability, but do not have the ethical issues associated with other sources of SCs. Therefore,
appropriate preservation procedures for dental SCs and teeth are now needed. Here, we discuss the
opportunities for tooth-banking (as it is now clinically feasible and commercially available), the advantages and
limitations of current cryopreservation techniques for dental SCs/teeth or tissues, and the current status of tooth
banks.
Dental Stem Cells and Tooth Banking for Regenerative Medicine
J Exp Clin Med 2010;2(3):111–117
Yen-Hua Huang1,5, Jen-Chang Yang2,5, Chin-Wei Wang3,4, Sheng-Yang Lee3,4,5*1Department of Biochemistry, Graduate Institute of
Medical Sciences, School of Medicine; Center for Reproductive Medicine, Taipei Medical University Hospital, Taipei Medical University,
Taipei, Taiwan 2School of Dental Technology, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan 3Department of
Dentistry, Wan-Fang Hospital, Taipei Medical University, Taipei, Taiwan 4School of Dentistry, Taipei Medical University, Taipei, Taiwan
5Center for Teeth Bank and Dental Stem Cell Technology, Taipei Medical University, Taipei, Taiwan
DecidousTeethpromisingandimportantsourcefor
regenerativetherapy
Cryopreserved dental pulp tissues of exfoliated deciduous teeth is a feasible
stemcell resource for regenerative medicine.
Human exfoliated deciduous teeth have been considered to be a promising source for regenerative therapy
because they contain unique postnatal stem cells from human exfoliated deciduous teeth (SHED) with self-
renewal capacity, multipotency and immunomodulatory function. However preservation technique of deciduous
teeth has not been developed. This study aimed to evaluate that cryopreserved dental pulp tissues of
humanexfoliated deciduous teeth is a retrievable and practical SHED source for cell-based therapy. SHED
isolated from the cryopreserved deciduous pulp tissues for over 2 years (25-30 months) (SHED-Cryo) owned
similarstem cell properties including clonogenicity, self-renew, stem cell marker expression, multipotency, in vivo
tissue regenerative capacity and in vitro immunomodulatory function to SHED isolated from the fresh tissues
(SHED-Fresh). To examine the therapeutic efficacy of SHED-Cryo on immune diseases, SHED-Cryo were
intravenously transplanted into systemic lupus erythematosus (SLE) model MRL/lpr mice. Systemic SHED-Cryo-
transplantation improved SLE-like disorders including short lifespan, elevated autoantibody levels and nephritis-
like renal dysfunction. SHED-Cryo amended increased interleukin 17-secreting helper T cells in MRL/lpr mice
systemically and locally. SHED-Cryo-transplantation was also able to recover osteoporosis bone reduction in
long bones of MRL/lpr mice. Furthermore, SHED-Cryo-mediated tissue engineering induced bone regeneration
in critical calvarial bone-defect sites of immunocompromised mice. The therapeutic efficacy ofSHED-Cryo
transplantation on immune and skeletal disorders was similar to that of SHED-Fresh. These data suggest that
cryopreservation of dental pulp tissues of deciduous teeth provide a suitable and desirable approach for stem
cell-based immune therapy and tissue engineering in regenerative medicine.
PLoS One. 2012;7(12):e51777. doi: 10.1371/journal.pone.0051777. Epub 2012 Dec 14
Ma L, MakinoY,Yamaza H,Akiyama K, HoshinoY, Song G, KukitaT, Nonaka K, Shi S,YamazaT.
Department of Molecular Cell Biology and Oral Anatomy, Graduate School of Dental Science, Kyushu University, Fukuoka, Japan ;
Department of Pediatric Dentistry, Graduate School of Dental Science, Kyushu University, Fukuoka, Japan.
4
5. Summary: Human adult mesenchymal stem cells (MSCs)are rare elements living in various organs
(e.g.bone marrow,skeletal muscle),with capability to differentiate in various cell types (e.g.
chondrocytes,adipocytes and osteoblasts).In the year 2000,Gronthos and co-workers isolated stem
cells from the human dental pulp (DPSCs).Later on,stem cells from exfoliated tooth were also obtained.
The aims of our study were to establish protocol of DPSCs isolation and to cultivate DPSCs either from
adult or exfoliated tooth,and to compare these cells with mesenchymal progenitor cell (MPCs)cultures.
MPCs were isolated from the human bone marrow of proximal femur.DPSCs were isolated from
deciduous and permanent teeth.Both cell types were cultivated under the same conditions in the media
with 2 % of FCS supplemented with PDGF and EGF growth factors.We have cultivated
undifferentiated DPSCs for long time,over 60population doublings in cultivation media designed for
bone marrow MPCs.After reaching Hayflick’s limit,they still have normal karyotype.Initial doubling time
of our cultures was from 12to 50hours for first 40population doublings,after reaching 50population
doublings,doubling time had increased to 60– 90hours.Regression analysis of uncumulated
population doublings proved tight dependence of population doublings on passage number and slow
decrease of proliferation potential.In comparison with bone marrow MPCs,DPSCs share similar
biological characteristics and stem cell properties.The results of our experiments proved that the
DPSCs and MPCs are highly proliferative,clonogenic cells that can be expanded beyond Hayflick’s
limit and remain cytogenetically stable.Moreover we have probably isolated two different populations
of DPSCs.These DPSCs lines differed one from another in morphology.Because of their high
proliferative and differentiation potential,DPSCs can become more attractive,easily accessible source
of adult stem cells for therapeutic purposes.
Human Dental Pulp Stem Cells – Isolation and Long Term
Cultivation
` 1 ~ 2 1 2 1 3
Jakub Such anek ,Toma`s ,Romana Ivanèakov ,Jana Karbanov ,VìraHubkov ,Robert Pytlik ,
` 4
Lenka Kuèerov a
Charles University in Prague,Faculty of Medicine in Hradec Kralove and University Hospital Hradec Kralove,Czech Republic,
Department of Dentistry1,Department of Histology and Embryology2,Department of Clinical Genetics4;Charles
University in Prague, 1st Medical Faculty in Prague,Teaching Hospital,Czech Republic: 1st Department of Medicine3
` ` `
a a a
DentalPulppresentsaneasyaccessible
sourceofstemcells
Abstract
Dental pulp (DP) can be extracted from child's primary teeth (deciduous), whose loss occurs spontaneously by
about 5 to 12 years. Thus, DP presents an easy accessible source of stem cells without ethical concerns.
Substantial quantities of stem cells of an excellent quality and at early (2-5) passages are necessary for clinical
use, which currently is a problem for use of adult stem cells. Herein, DPs were cultured generating stem cells at
least during six months through multiple mechanical transfers into a new culture dish every 3-4 days. We
compared stem cells isolated from the same DP before (early population, EP) and six months after several
mechanical transfers (late population, LP). No changes, in both EP and LP, were observed in morphology,
expression of stem cells markers (nestin, vimentin, fibronectin, SH2, SH3 and Oct3/4), chondrogenic and
myogenic differentiation potential, even after cryopreservation. Six hours after DP extraction and in vitro plating,
rare 5-bromo-2'-deoxyuridine (BrdU) positive cells were observed in pulp central part. After 72 hours, BrdU
positive cells increased in number and were found in DP periphery, thus originating a multicellular population of
stem cells of high purity. Multiple stem cell niches were identified in different zones of DP, because abundant
expression of nestin, vimentin and Oct3/4 proteins was observed, while STRO-1 protein localization was
restricted to perivascular niche. Our finding is of importance for the future of stem cell therapies, providing scaling-
up of stem cells at early passages with minimum risk of losing their "stemness".
PMCID: PMC3387222
Scaling-up of dental pulp stem cells isolated from multiple niches.
PLoS One. 2012;7(6):e39885. doi: 10.1371/journal.pone.0039885. Epub 2012 Jun 29.
Lizier NF, KerkisA, Gomes CM, Hebling J, Oliveira CF, CaplanAI, Kerkis I.
Laboratory of Genetics, Butantan Institute, Sao Paulo, SP, Brazil. nelson_lizier@yahoo.com.br
Stemade Comments: Dental Stem Cells have shown excellent potential for
expansion and culturing without loosing their “Stemness”
5
6. Abstract
In this study we used a biocomplex constructed from dental pulp stem/progenitor cells (DPCs) and a collagen
sponge scaffold for oro-maxillo-facial (OMF) bone tissue repair in patients requiring extraction of their third
molars. The experiments were carried out according to our Internal Ethical Committee Guidelines and written
informed consent was obtained from the patients. The patients presented with bilateral bone reabsorption of
the alveolar ridge distal to the second molar secondary to impaction of the third molar on the cortical alveolar
lamina, producing a defect without walls, of at least 1.5 cm in height. This clinical condition does not permit
spontaneous bone repair after extraction of the third molar, and eventually leads to loss also of the adjacent
second molar. Maxillary third molars were extracted first for DPC isolation and expansion. The cells were then
seeded onto a collagen sponge scaffold and the obtained biocomplex was used to fill in the injury site left by
extraction of the mandibular third molars. Three months after autologous DPC grafting, alveolar bone of
patients had optimal vertical repair and complete restoration of periodontal tissue back to the second molars,
as assessed by clinical probing and X-rays. Histological observations clearly demonstrated the complete
regeneration of bone at the injury site. Optimal bone regeneration was evident one year after grafting. This
clinical study demonstrates that a DPC/collagen sponge biocomplex can completely restore human
mandible bone defects and indicates that this cell population could be used for the repair and/or regeneration
of tissues and organs.
Human Mandible Bone Defect Repair by The Grafting of Dental Pulp Stem/
progenitor Cells and Collagen Sponge Biocomplexes
Riccardo d’Aquino1,2, Alfredo De Rosa1, Vladimiro Lanza1, Virginia Tirino2, Luigi Laino1, Antonio Graziano1, Vincenzo
Desiderio2, Gregorio Laino1 and Gianpaolo Papaccio2*
Dipartimento di Discipline Odontostomatologiche, Ortodontiche e Chirurgiche, 2Dipartimento di Medicina Sperimentale, Sezione di
Istologia ed Embriologia,Tissue Engineering and Regenerative Medicine (TERM) Division, SecondoAteneo di Napoli, Naples, Italy
9
DentalStemCellsforRepairofMandible
BoneDefect
DentalStemCellsuseforBoneRegeneration
Stromal stem cells from human dental pulp (SBP-DPSCs) were used to study osteogenic differentiation in
vitro and in vivo. We previously reported that SBP-DPSCs are multipotent stem cells able to differentiate into
osteoblasts, which synthesize three dimensional woven bone tissue chips in vitro. In this study, we followed
the temporal expression pattern of speci?c markers in SBP-DPSCs and found that, when differentiating into
osteoblasts, they express, besides osteocalcin, also ?k-1 (VEGF-R2). In addition, 30% of them expressed
speci?c antigens for endothelial cells, including CD54, von-Willebrand (domain 1 and 2), CD31 (PECAM-1)
and angiotensin-converting enzyme. Interestingly, we found endotheliocytes forming vessel walls, observing
that stem cells synergically differentiate into osteoblasts and endotheliocytes, and that ?k-1 exerts a pivotal
role in coupling osteoblast and endotheliocyte differentiation. When either SBP-DPSCs or bone chips
obtained in vitro were transplanted into immunocompromised rats, they generated a tissue structure with an
integral blood supply similar to that of human adult bone; in fact, a large number of HLA-1 þ vessels were
observed either within the bone or surrounding it in a periosteal layer. This study provides direct evidence to
suggest that osteogenesis and angiogenesis mediated by human SBP-DPSCs may be regulated by distinct
mechanisms, leading to the organization of adult bone tissue after stem cell transplantion.
Cell Death and Differentiation (2007) 14, 1162–1171. doi:10.1038/sj.cdd.4402121; published online 9 March 2007
Human postnatal dental pulp cells co-differentiate into osteoblasts and
endotheliocytes: a pivotal synergy leading to adult bone tissue formation
R d’Aquino1,2,5,AGraziano2,5, M Sampaolesi3, G Laino1, G Pirozzi4,ADe Rosa1 and G Papaccio*,2
8
7. Sinus Lift Augmentation Using Autologous Pulp Stem Cells:
Case Report Of Bone Density Evaluation
Bone augmentation to reconstruct atrophic jaws provides the base for sufficient functional and aesthetic
implant-supported oral rehabilitation. Although autografts are the standard procedure for bone grafting, the
use of bone regeneration by means of dental pulp stem cell is an alternative that open a new era in this field. In
March 2010, at the Department of Oral Surgery, Don Orione Hospital, Bergamo, Italy, one patient undergo to
sinus lift elevation with pulp stem cells gentle poured onto collagen sponge. A CT scan control was
performed after 4 month and DICOM data were processed with medical imaging software which gives the
possibility to use a virtual probe to extract the bone density. Pearson’s chi-square test was used to investigate
difference in bone density (i.e. BD) between native and newly formed bone. BD in newly formed bone is about
the double of native bone. This report demonstrated that stem cells derived from dental pulp poured onto
collagen sponge is a useful method for bone regeneration in atrophic maxilla.
G. BRUNELLI1,A. MOTRONI2, F. CARINCI3,A. GRAZIANO3,
R. D’AQUINO3, I. ZOLLINO3, R. MONGUZZI3,
Don Orione Hospital, Bergamo, Italy
2AMIRG (Applied Medical Imaging Research Group), Milan, Italy
3 Department of D.M.C.C.C., Section of Maxillofacial and Plastic Surgery, University of Ferrara, Ferrara, Italy
Lancet. 2008 May 10;371(9624):1579-86. doi: 10.1016/S0140-6736(08)60690-X.
11
Pleasemailthebulletpoint
MesenchymalStemCellsusedforSinus
augmentation
PURPOSE: Mesenchymal stem cells (MSCs) have been applied in maxillary sinus augmentation (MSA) with
clinically successful results. The purpose of this article was to evaluate the systematically acquired evidence for
the effectiveness of cell-based approaches in MSA with various scaffolds, and to narratively assess evidence
from additional articles that report effectiveness of cell-based approaches in MSA.
MATERIALS AND METHODS: Electronic database searches were performed. Inclusion criteria were studies
of cell-based approaches in MSA with various scaffolds, in humans, with at least 3 to 4 months of follow-up.
Meta-analysis was performed for randomized controlled trials (RCTs) with histologic/histomorphometric
evaluation.
RESULTS: Fifteen studies (4 RCTs) were considered to be eligible for inclusion in the review. The meta-analysis
suggested a marginal, nonstatistically significant positive effect of MSCs on the bone regrowth.
CONCLUSIONS: A number of studies have demonstrated the potential for cell-based approaches in MSA;
further RCTs that clearly demonstrate benefits of cell-based approach are needed.
Maxillary sinus augmentation with adult mesenchymal stem cells: a review of the
current literature.
Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Jan 9. pii: S2212-4403(12)01627-6. doi: 10.1016/j.oooo.2012.09.087. Mangano
FG,Tettamanti L, Sammons RL,Azzi L, CaprioglioA, MacchiA, Mangano C
Dental School, University of Insubria, Varese, Italy. Electronic address: francescomangano1@mclink.net.
10
8. Abstract
The need for new dental tissue-replacement therapies is evident in recent reports which reveal startling
statistics regarding the high incidence of tooth decay and tooth loss. Recent advances in the identification
and characterization of dental stem cells, and in dental tissue-engineering strategies, suggest that
bioengineering approaches may successfully be used to regenerate dental tissues and whole teeth. Interest
in dental tissue-regeneration applications continues to increase as clinically relevant methods for the
generation of bioengineered dental tissues, and whole teeth, continue to improve. This paper is concerned
about dental-derived stem cells and their characterization. Additionally, since conventional dental treatments
partially serve the purpose for replacing missing teeth and always include possible failure rates, the potential
of dental-derived stem cells in promoting whole tooth regeneration is also discussed.
Dental-derived Stem Cells and whole Tooth Regeneration: an Overview
Aous Dannan
DentalStemCellsforwhole
ToothRegeneration
6
Repair of alveolar cleft defect with mesenchymal stem cells and platelet
derived growth factors: a preliminary report.
The purpose of this study was to evaluate the enhancing effect of recombinant platelet derived growth factor
on human mesenchymal stem cells(hMSCs) in secondary alveoloplasty. Three patients with 4 alveolar
defects were selected for this study. Mesenchymal stem cells were cultured from a posterior iliac bone
aspirate. MSCs were mounted on biphasic scaffolds and combined with platelet derived growth factor
(PDGF) in the operating room to make a triad of the scaffold, growth factor, and cells. The triads were placed
in anterior maxillary cleft defects and closed with lateral advancement gingival flaps. The postoperative cleft
bone volume was measured with cone beam computed tomography scans. A mean of 51.3% fill of the bone
defect was calculated 3 months post-operation. Our data suggests the use of recombinant platelet derived
growth factor with hMSCs may enhance the regeneration capacity of the cells.
J Craniomaxillofac Surg. 2012 Jan;40(1):2-7. doi: 10.1016/j.jcms.2011.02.003. Epub 2011 Mar 21. Behnia H, Khojasteh A,
Soleimani M,TehranchiA,AtashiA.
Department of Oral and Maxillofacial Surgery, Dental Research Center, Shahid Beheshti University of Medical Sciences, Tehran,
Iran.
MesenchymalStemCellsusedto
treatAlveolarcleftdefect
12
9. PMID: 19614680 [PubMed - indexed for MEDLINE]
DentalStemCellshavingsamecharacteristicsaslimbalstemcells
Human immature dental pulp stem cells share key characteristic features with
limbal stem cells.
ABSTRACT
OBJECTIVES: Limbal stem cells (LSC) are self-renewing, highly proliferative cells in vitro, which express a set of
specific markers and in vivo have the capacity to reconstruct the entire corneal epithelium in cases of ocular
surface injury. Currently, LSC transplantation is a commonly used procedure in patients with either uni- or bilateral
total limbal stem cells deficiency (TLSCD). Although LSC transplantation holds great promise for patients, several
problems need to be overcome. In order to find an alternative source of cells that can partially substitute LSC in
cornea epithelium reconstruction, we aimed at investigating whether human immature dental pulp stem cells
(hIDPSC) would present similar key characteristics as LSC and whether they could be used for corneal surface
reconstruction in a rabbit TLSCD model.
MATERIALS: We used hIDPSC, which co-express mesenchymal and embryonic stem cell markers and present
the capacity to differentiate into derivative cells of the three germinal layers. TLSCD was induced by chemical burn
in one eye of rabbits. After 30 days, the opaque tissue formed was removed by superficial keratectomy.
Experimental group received undifferentiated hIDPSC, while control group only received amniotic membrane
(AM). Both groups were sacrificed after 3 months.
RESULTS AND CONCLUSIONS: We have demonstrated, using immunohistochemistry and reverse
transcription-polymerase chain reaction, that hIDPSCs express markers in common with LSC, such as ABCG2,
integrin beta1, vimentin, p63, connexin 43 and cytokeratins 3/12. They were also capable of reconstructing the
eye surface after induction of unilateral TLSCD in rabbits, as shown by morphological and immunohistochemical
analysis using human-specific antibodies against limbal and corneal epithelium. Our data suggest that hIDPSCs
share similar characteristics with LSC and might be used as a potential alternative source of cells for corneal
reconstruction.
Cell Prolif. 2009 Oct;42(5):587-94. Epub 2009 Jul 14.
Monteiro BG, Serafim RC, Melo GB, Silva MC, Lizier NF, Maranduba CM, Smith RL, KerkisA, Cerruti H, Gomes JA, Kerkis I.
Source: Genetics Laboratory, Butantan Institute, São Paulo, SP, Brazil.
20
DentalPulpMesenchymalStemCellsreconstructcornea
Corneal Reconstruction with Tissue-Engineered Cell Sheets Composed of
Human Immature Dental Pulp Stem Cells
PURPOSE: To determine the outcome of the use of a tissue-engineered cell sheet composed of human
undifferentiated immature dental pulp stem cells (hIDPSC) for ocular surface reconstruction in an animal model of
total limbal stem cell deficiency (LSCD).
METHODS: LSCD was induced by the application of 0.5 M NaOH to the right eye of rabbits for 25 seconds (mild
chemical burn [MCB]) and for 45 seconds (severe chemical burn [SCB]). After 1 month, a superficial keratectomy
was performed to remove the fibrovascular pannus that covered the animals' burned corneas. A tissue-
engineered hIDPSC sheet was transplanted onto the corneal bed and then covered with deepithelialized human
amniotic membrane (AM). In the respective control groups, the denuded cornea was covered with AM only. After 3
months, a detailed analysis of the rabbit eyes was performed with regard to clinical aspect, histology, electron
microscopy, and immunohistochemistry.
RESULTS: Corneal transparency of the rabbit eyes that underwent hIDPSC transplantation was improved
throughout the follow-up, while the control corneas developed total conjunctivalization and opacification. Rabbits
from the MCB group showed clearer corneas with less neovascularization. The clinical data were confirmed by
histologic analysis that showed healthy uniform corneal epithelium, especially in the MCB group. The presence of
hIDPSC was detected using an anti- hIDPSC antibody. The corneal tissue also showed positive
Investigative Ophthalmology & Visual Science, March 2010, Vol. 51, No. 3
Jose´ A´ lvaro Pereira Gomes,*,1 Ba´byla Geraldes Monteiro,2,3 Gustavo Barreto Melo,1 Ricardo Luiz Smith,4 Marcelo Cavenaghi
Pereira da Silva,4 Nelson Foresto Lizier,3,4Alexandre Kerkis,5 Humberto Cerruti,6 and Irina Kerkis*,3
1Centro Avanc¸ado de Superfície Ocular (CASO) and Setor de Co´rnea e Doenc¸as Externas, Instituto da Visa˜o, Universidade Federal
de Sa˜o Paulo, Sa˜o Paulo, Brazil; 3Laborato´rio de Gene´tica, Instituto Butan-tan, Instituto Nacional de Cieˆncia e Tecnologia em
Ce´lulas-Tronco eTerapia Celular (INCTC), Sa˜o Paulo, Brazil; 4Departamento de Morfo-logia e Gene´tica da Universidade Federal de
Sa˜o Paulo, Sa˜o Paulo,Brazil; 5Gene´tica Aplicada, Atividades Veterina´rias Ltda., Centro deInovac¸a˜o Tecnolo´gica, Sa˜o Paulo,
Brazil; and 6Clínica e Centro de Pesquisa Odontolo´gica-CERA, Sa˜o Paulo, Brazil.
21
10. AutologousOralMucosalEpitheliumforCorneal
Reconstruction
BACKGROUND: Ocular trauma or disease may lead to severe corneal opacification and, consequently, severe
loss of vision as a result of complete loss of corneal epithelial stem cells. Trans-plantation of autologous corneal
stem-cell sources is an alternative to allograft trans-plantation and does not require immunosuppression, but it is
not possible in many cases in which bilateral disease produces total corneal stem-cell deficiency in both eyes. We
studied the use of autologous oral mucosal epithelial cells as a source of cells for the reconstruction of the corneal
surface.
METHODS: We harvested 3-by-3-mm specimens of oral mucosal tissue from four patients with bilateral total
corneal stem-cell deficiencies. Tissue-engineered epithelial-cell sheets were fabricated ex vivo by culturing
harvested cells for two weeks on temperature-responsive cell-culture surfaces with 3T3 feeder cells that had been
treated with mi-tomycin C. After conjunctival fibrovascular tissue had been surgically removed from the ocular
surface, sheets of cultured autologous cells that had been harvested with a sim-ple reduced-temperature
treatment were transplanted directly to the denuded corneal surfaces (one eye of each patient) without sutures.
RESULTS: Complete reepithelialization of the corneal surfaces occurred within one week in all four treated eyes.
Corneal transparency was restored and postoperative visual acuity im-proved remarkably in all four eyes. During
a mean follow-up period of 14 months, all corneal surfaces remained transparent. There were no complications.
CONCLUSIONS: Sutureless transplantation of carrier-free cell sheets composed of autologous oral mu-cosal
epithelial cells may be used to reconstruct corneal surfaces and can restore vision in patients with bilateral severe
disorders of the ocular surface.
Corneal Reconstruction with Tissue- Engineered Cell Sheets Composed of
Autologous Oral Mucosal Epithelium
Kohji Nishida, M.D., Ph.D., Masayuki Yamato, Ph.D., Yasutaka Hayashida, M.D., Katsuhiko Watanabe, M.Sc., Kazuaki Yamamoto,
M.Sc., Eijiro Adachi, M.D., Ph.D., Shigeru Nagai, M.Sc., Akihiko Kikuchi, Ph.D., Naoyuki Maeda, M.D., Ph.D., Hitoshi Watanabe, M.D.,
Ph.D.,Teruo Okano, Ph.D., andYasuoTano, M.D., Ph.D.
n engl j med 351;12 www.nejm.org september 16, 2004
19
Mesenchymalcellsforcornealrecunstruction
ABSTRACT
PURPOSE: Ocular burns can damage the corneal epithelial stem cells located at the limbus. This study
evaluated the efficacy of xeno-free autologous cell-based treatment of limbal stem cell deficiency.
METHODS: This retrospective study included 200 patients, above 8 years of age, with clinically diagnosed
unilateral total limbal stem cell deficiency due to ocular surface burns treated between 2001 and 2010. A small
limbal biopsy was obtained from the unaffected eye. The limbal epithelial cells were expanded ex vivo on
human amniotic membrane for 10e14 days using a xeno-free explant culture system. The resulting cultured
epithelial monolayer and amniotic membrane substrate were transplanted on to the patient's affected eye.
Postoperative corneal surface stability, visual improvement and complications were objectively analysed.
RESULTS: A completely epithelised, avascular and clinically stable corneal surface was seen in 142 of 200
(71%) eyes at a mean follow-up of 361.6 (range: 1e7.6) years. A two-line improvement in visual acuity, without
further surgical intervention, was seen in 60.5% of eyes. All donor eyes remained healthy.
CONCLUSIONS: Autologous cultivated limbal epithelial transplantation using a xeno-free explant culture
Clinical outcomes of xeno-free autologous cultivated limbal epithelial
transplantation: a 10-year study
BJO 10.1136/bjophthalmol-2011-300352 Virender S Sangwan,1,2 Sayan Basu,1,2 Geeta K Vemuganti,2 Kunjal Sejpal,1 Sandhya
V Subramaniam,3 Souvik Bandyopadhyay,4 Sannapaneni Krishnaiah,5 Subhash Gaddipati,2,6 Shubha Tiwari,2,6 Dorairajan
Balasubramanian2,3,6
1Cornea and Anterior Segment Services, L V Prasad Eye Institute, Hyderabad, India 2Sudhakar and Sreekanth Ravi Stem Cell
Biology Laboratory, L V Prasad Eye Institute, Hyderabad, India 3Professor Brien Holden Eye Research Center, L V Prasad Eye
Institute, Hyderabad, India 4Indian Institute of Public Health, Hyderabad, India 5Department of Clinical Epidemiology and
Biostatistics, L V Prasad Eye Institute, Hyderabad, India 6Champalimaud Translational Center for Eye Research, LV Prasad Eye
Institute, Hyderabad, India
15
11. limbalepithelialtransplantationfortreatingunilateral
limbalstemcelldeficiencyfollowingocularburns.
Simple limbal epithelial transplantation (SLET): a novel surgical technique for
the treatment of unilateral limbal stem cell deficiency
ABSTRACT
This study describes a novel surgical technique of limbal transplantation, which combines the benefits of
existing techniques while avoiding their difficulties. Six patients with unilateral and total limbal stem cell
deficiency following ocular surface burns underwent a single-stage procedure. A 232 mm strip of donor limbal
tissue was obtained from the healthy eye and divided into eight to ten small pieces. After surgical preparation
of the recipient ocular surface, these tiny limbal transplants were distributed evenly over an amniotic
membrane placed on the cornea. After surgery, a completely epithelialised, avascular and stable corneal
surface was seen in all recipient eyes by 6 weeks, and this was maintained at a mean6SD follow-up of 9.261.9
months. Visual acuity improved from worse than 20/200 in all recipient eyes before surgery to 20/60 or better in
four (66.6%) eyes, while none of the donor eyes developed any complications. This technique requires less
donor tissue than previously used for conventional autografting and does not need a specialist laboratory for
cell expansion. Although long-term results are awaited, this simple limbal epithelial transplantation promises
to be an easy and effective technique for treating unilateral limbal stem cell deficiency following ocular burns.
Virender S Sangwan,1,2 Sayan Basu,1,2 Sheila MacNeil,3 Dorairajan Balasubramanian4 <Additional materials are published online
only. To view these files please visit the journal online (http://bjo.bmj. com/content/early/recent). 1Cornea and Anterior Segment
Services, L V Prasad Eye Institute, Hyderabad, India 2Sudhakar and Sreekanth Ravi Stem Cell Biology Laboratory, L V Prasad Eye
Institute, Hyderabad, India 3Department of Materials Science and Engineering, University of Sheffield, Sheffield, UK
4Champalimaud Translational Centre for Eye Research, Hyderabad Eye Research Foundation, L V Prasad Eye Institute,
Hyderabad, India
16
Intracoronary autologous bone-marrow cell transfer after myocardial infarction:
the BOOST randomised controlled clinical trial
SUMMARY
BACKGROUND: Emerging evidence suggests that stem cells and progenitor cells derived from bone marrow
can be used to improve cardiac function in patients after acute myocardial infarction. In this randomised trial, we
aimed to assess whether intracoronary transfer of autologous bone-marrow cells could improve global left-
ventricular ejection fraction (LVEF) at 6 months' follow-up.
METHODS: After successful percutaneous coronary intervention (PCI) for acute ST-segment elevation
myocardial infarction, 60 patients were randomly assigned to either a control group (n=30) that received
optimum postinfarction medical treatment, or a bone-marrow-cell group (n=30) that received optimum medical
treatment and intracoronary transfer of autologous bone-marrow cells 4·8 days (SD 1·3) after PCI. Primary
endpoint was global left-ventricular ejection fraction (LVEF) change from baseline to 6 months' follow-up, as
determined by cardiac MRI. Image analyses were done by two investigators blinded for treatment assignment.
Analysis was per protocol.
FINDINGS: Global LVEF at baseline (determined 3·5 days [SD 1·5] after PCI) was 51·3 (9·3%) in controls and 50·0
(10·0%) in the bone-marrow cell group (p=0·59). After 6 months, mean global LVEF had increased by 0·7
percentage points in the control group and 6·7 percentage points in the bone-marrow-cell group (p=0·0026).
Transfer of bone-marrow cells enhanced left-ventricular systolic function primarily in myocardial segments
adjacent to the infarcted area. Cell transfer did not increase the risk of adverse clinical events, in stent restenosis,
or proarrhythmic effects.
INTERPRETATION: Intracoronary transfer of autologous bone-marrow-cells promotes improvement of left-
ventricular systolic function in patients after acute myocardial infarction.
Kai C Wollert MD a, Gerd P Meyer MD a, Joachim Lotz MD b, Stefanie Ringes Lichtenberg MD a, Peter Lippolt MD a, Christiane
Breidenbach MD a, Stephanie Fichtner BS a, Thomas Korte MD a, Burkhard Hornig MD a, Diethelm Messinger MSc d, LubomirArseniev
MD c, Bernd Hertenstein MD c, ProfArnold Ganser MD c, Prof Helmut Drexler MD
The Lancet, Volume 364, Issue 9429, Pages 141 - 148, 10 July 2004
doi:10.1016/S0140-6736(04)16626-9
StemCellsimproveleft-ventricularsystolicfunction
afteracutemyocardialinfarction
22
12. 14
StemCellTherapyforMyocardialInfarctionStemCellTherapyimprovesventricularperformance,
qualityoflifeandsurvivalinpatientswithheartfailure
AIMS: We assessed whether a single intracoronary infusion of autologous bone marrow cells (BMCs) can have a
sustained impact on left ventricular ejection fraction (LVEF) in patients after ST-elevation myocardial infarction
(STEMI). In the BOne marrOw transfer to enhance ST-elevation infarct regeneration (BOOST) trial, 60 patients with
STEMI and successful percutaneous coronary intervention were randomized to a control and a cell therapy
group. As previously reported, BMC transfer led to an improvement of LVEF by 6.0% at 6 months (P ¼ 0.003) and
2.8% at 18 months (P ¼ 0.27).
METHODS: and results Left ventricular ejection fraction and clinical status were re-assessed in all surviving
patients after 61+11 months. Major adverse cardiac events occurred with similar frequency in both groups. When
compared with baseline, LVEF assessed by magnetic resonance imaging at 61 months decreased by 3.3+9.5%
in the control group and by 2.5+11.9% in the BMC group (P ¼ 0.30). Patients with an infarct transmurality . median
appeared to benefit from BMC transfer throughout the 61-month study period (P ¼ 0.040).
CONCLUSION: A single intracoronary application of BMCs does not promote a sustained improvement of LVEF
in STEMI patients with relatively preserved systolic function. It is conceivable that a subgroup of patients with
more transmural infarcts may derive a sustained benefit from BMC therapy. However, this needs to be tested
prospectively in a randomized trial.
KEYWORDS: Acute myocardial infarction • Cell therapy • Magnetic resonance imaging
Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-
up from the randomized-controlled BOOST trial
Gerd P. Meyer1*†, Kai C. Wollert1†, Joachim Lotz2, Jens Pirr1, Ulrike Rager1, Peter Lippolt1, Andreas Hahn3, Stephanie
Fichtner1,Arnd Schaefer1, LubomirArseniev4,Arnold Ganser4, and Helmut Drexler1,
1Department of Cardiology andAngiology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany; 2Department of
Diagnostic Radiology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany; 3Department of Biometrics,
Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany; and 4Department of Hematology, Hemostaseology,
Oncology, and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany Received 15
October 2008; revised 19 July 2009; accepted 20August 2009; online publish-ahead-of-print 22 September 2009
AIMS: Despite accumulated evidence that intracoronary bone marrow cell (BMC) therapy may be beneficial in
acute myocardial infarction, there are only limited data available on the effectiveness of BMC’s in chronic heart
failure. The aim of this study was to quantitatively investigate ventricular haemodynamics, geometry, and
contractility as well as the long-term clinical outcome of BMC treated patients with reduced left ventricular ejection
fraction (LVEF) due to chronic ischaemic cardiomyopathy.
METHODS AND RESULTS: Patients with chronic heart failure (n ¼ 391 LVEF ≤ 35%) due to ischaemic
cardiomyopathy were enrolled in the present study. Of these, 191 patients (mean NYHA class 3.22) underwent
intracoronary BMC therapy. The control group (mean NYHA class 3.06) consisted of 200 patients with
comparable LVEF. Assessments of haemodynamics at rest and exercise, quantitative ventriculography,
spiroergometry, 24 h Holter ECG, late potentials, and heart rate variability were analysed. Over 3 months to 5
years after intracoronary BMC therapy there was a significant improvement in haemodynamics (e.g. LVEF,
cardiac index), exercise capacity, oxygen uptake, and LV contractility. Importantly, there was a significant
decrease in long-term mortality in the BMC treated patients compared with the control group.
CONCLUSION: Intracoronary BMC therapy improves ventricular performance, quality of life and survival in
patients with heart failure.These effects were present when BMC were administered in addition to standard
therapeutic regimes. No side effects were observed.
KEYWORDS: Ischaemic cardiomyopathy • Chronic heart failure • Bone marrow cell therapy • Remodelling •
Mortality
The acute and long-term effects of intracoronary Stem cell Transplantation in 191
patients with chronic heARt failure: the STAR-heart study
Bodo-Eckehard Strauer*, MuhammadYousef, and Christiana M. Schannwell
From the Department of Medicine, Division of Cardiology, Pneumology and Angiology, Heinrich-Heine-University of Du¨sseldorf,
Moorenstr 5, 40225 Du¨sseldorf, Germany Received 11 February 2010; revised 12April 2010; accepted 16April 2010
See page 642 for the editorial comment on this article (doi:10.1093/eurheartj/hfq105)
23
24
13. 15
Transplantation of Progenitor Cells and Regeneration Enhancement in Acute
Myocardial Infarction (TOPCARE-AMI)
ABSTRACT
BACKGROUND: Experimental studies suggest that transplantation of blood-derived or bone marrow–derived
progenitor cells beneficially affects postinfarction remodeling. The safety and feasibility of autologous progenitor
cell transplantation in patients with ischemic heart disease is unknown.
METHODS AND RESULTS: We randomly allocated 20 patients with reperfused acute myocardial infarction (AMI)
to receive intracoronary infusion of either bone marrow–derived (n=9) or circulating blood–derived progenitor
cells (n=11) into the infarct artery 4.3±1.5 days after AMI. Transplantation of progenitor cells was associated with
a significant increase in global left ventricular ejection fraction from 51.6±9.6% to 60.1±8.6% (P=0.003),
improved regional wall motion in the infarct zone (- 1.5±0.2 to - 0.5±0.7 SD/chord; P<0.001), and profoundly
reduced end-systolic left ventricular volumes (56.1±20 mL to 42.2±15.1 mL; P=0.01) at 4-month follow-up. In
contrast, in a nonrandomized matched reference group, left ventricular ejection fraction only slightly increased
from 51±10% to 53.5±7.9%, and end-systolic volumes remained unchanged. Echocardiography revealed a
profound enhancement of regional contractile function (wall motion score index 1.4±0.2 at baseline versus
1.19±0.2 at follow-up; P<0.001). At 4 months, coronary blood flow reserve was significantly (P<0.001) increased
in the infarct artery. Quantitative F-18-fluorodeoxyglucose–positron emission tomography analysis revealed a
significant (P<0.01) increase in myocardial viability in the infarct zone. There were no differences for any
measured parameter between blood-derived or bone marrow–derived progenitor cells. No signs of an
inflammatory response or malignant arrhythmias were observed.
CONCLUSIONS: In patients with AMI, intracoronary infusion of autologous progenitor cells appears to be
feasible and safe and may beneficially affect postinfarction remodeling processes.
Birgit Assmus, MD; Volker Schächinger, MD; Claudius Teupe, MD;Martina Britten, MD; Ralf Lehmann, MD; Natascha Döbert, MD;Frank
Grünwald, MD; Alexandra Aicher, MD; Carmen Urbich, PhD;Hans Martin, MD; Dieter Hoelzer, MD; Stefanie Dimmeler, PhD;Andreas M.
Zeiher, MD
Author Affiliations: From the Department of Molecular Cardiology and Department of Cardiology, Internal Medicine IV, (B.A., V.S., C.T.,
M.B., R.L., A.A., C.U.), Department of Nuclear Medicine (N.D., F.G.), and the Department of Hematology (H.M., D.H.), University of
Frankfurt, Frankfurt, Germany. Circulation.2002; 106: 3009-3017Published online before print November 11, 2002,doi:
10.1161/?01.CIR.0000043246.74879.CD
StemCellsUsedPostAcuteMyocardialInfarction
AIMS: To investigate the clinical outcome after intracoronary administration of autologous progenitor cells in
patients with acute myocardial infarction (AMI).
METHODS AND RESULTS: Using a double-blind, placebo-controlled multicentre trial design, we randomized
204 patients with successfully reperfused AMI to receive intracoronary infusion of bone-marrow-derived
progenitor cells (BMCs) or placebo medium into the infarct artery 3–7 days after successful infarct reperfusion
therapy. At 12 months, the pre-specified cumulative endpoint of death, myocardial infarction, or necessity for
revascularization was significantly reduced in the BMC group compared with placebo (P ¼ 0.009). Likewise, the
combined endpoint death, recurrence of myocardial infarction, and rehospitalization for heart failure was
significantly (P ¼ 0.006) reduced in patients receiving intracoronary BMC administration. Intracoronary
administration of BMC remained a significant predictor of a favourable clinical outcome by Cox regression
analysis, adjusting for classical predictors of poor outcome after AMI.
CONCLUSION: Intracoronary administration of BMCs is associated with a significant reduction of the occurrence
of major adverse cardiovascular events after AMI. Large-scale studies are warranted to confirm the effects of BMC
administration on mortality and morbidity in patients with AMIs.
KEYWORDS: Myocardial infarction; Prognosis; Cells;Catheterization
Improved clinical outcome after intracoronary administration of bone-marrow-
derived progenitor cells in acute myocardial infarction: final 1-year results of the
REPAIR-AMI trial
Volker Scha¨chinger1, Sandra Erbs2,Albrecht Elsa¨sser3, Werner Haberbosch4, Rainer Hambrecht2, Hans Ho¨lschermann5, Jiangtao
Yu6, Roberto Corti7, Detlef G. Mathey8, Christian W. Hamm3, Tim Su¨selbeck9, Nikos Werner10{, Ju¨rgen Haase11, Jo¨rg Neuzner12,
Alfried Germing13, Bernd Mark14, BirgitAssmus1, Torsten Tonn15, Stefanie Dimmeler16, andAndreas M. Zeiher1* for the REPAIR-AMI
Investigators
StemCellTherapyinTreatmentofAcute
MyocardialInfarction
25
26
14. Human dental pulp stem cells improve left ventricular function, induce
angiogenesis, and reduce infarct size in rats with acute myocardial infarction.
ABSTRACT
Human dental pulp contains precursor cells termed dental pulp stem cells (DPSC) that show self-renewal and
multilineage differentiation and also secrete multiple proangiogenic and antiapoptotic factors. To examine
whether these cells could have therapeutic potential in the repair of myocardial infarction (MI), DPSC were
infected with a retrovirus encoding the green fluorescent protein (GFP) and expanded ex vivo. Seven days
after induction of myocardial infarction by coronary artery ligation, 1.5 x 10(6) GFP-DPSC were injected
intramyocardially in nude rats. At 4 weeks, cell-treated animals showed an improvement in cardiac function,
observed by percentage changes in anterior wall thickening left ventricular fractional area change, in parallel
with a reduction in infarct size. No histologic evidence was seen of GFP+ endothelial cells, smooth muscle
cells, or cardiac muscle cellswithin the infarct. However, angiogenesis was increased relative to control-
treated animals. Taken together, these data suggest that DPSC could provide a novel alternative cell
population for cardiac repair, at least in the setting of acute MI.
Gandia C,ArmiñanA, García-Verdugo JM, Lledó E, RuizA, Miñana MD, Sanchez-Torrijos J, Payá R, Mirabet V, Carbonell-Uberos F,
Llop M, Montero JA,Sepúlveda P.
Source: Fundación Hospital General Universitario, Consorcio Hospital General Universitario de Valencia, Avenida Tres Cruces s/n,
46014 Valencia, Spain.
Stem Cells. 2008 Mar;26(3):638-45. Epub 2007 Dec 13.
DentalStemCellsimproveleftventricular
functionafteracutemyocardialinfarction
27
Stem cell therapy for type 1 diabetes mellitus: a review of recent
clinical trials
Abstract
Stem cell therapy is one of the most promising treatments for the near future. It is expected that this kind
of therapy can ameliorate or even reverse some diseases. With regard to type 1 diabetes, studies
analyzing the therapeutic effects of stem cells in humans began in 2003 in the Hospital das Clínicas of the
Faculty of Medicine of Ribeirão Preto - SP USP, Brazil, and since then other centers in different countries
started to randomize patients in their clinical trials. Herein we summarize recent data about beta cell
regeneration, different ways of immune intervention and what is being employed in type 1 diabetic
patients with regard to stem cell repertoire to promote regeneration and/or preservation of beta cell mass.
The Diabetes Control and Complications Trial (DCCT) was a 7-year longitudinal study that demonstrated
the importance of the intensive insulin therapy when compared to conventional treatment in the
development of chronic complications in patients with type 1 diabetes mellitus (T1DM). This study also
demonstrated another important issue: there is a reverse relationship between C-peptide levels
(endogenous indicator of insulin secretion) chronic complications - that is, the higher the C-peptide
levels, the lower the incidence of nephropathy, retinopathy and hypoglycemia. From such data, beta cell
preservation has become an additional target in the management ofT1DM [1].
Diabetology & Metabolic Syndrome 2009, 1:19 doi:10.1186/1758-5996-1-19
Carlos Eduardo Barra Couri* and Júlio César Voltarelli
Address: Department of Internal Medicine, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP,
Brazil Email: Carlos Eduardo Barra Couri* - ce.couri@yahoo.com.br; Júlio César Voltarelli - jcvoltar@fmrp.usp.br
* Corresponding author
15. 16
ABSTRACT
OBJECTIVE: To evaluate the effect of treatment of type 1 diabetes by transplantation of bone-derived stem
cells expressing human insulin gene.
METHODS: Murine bone marrow-derived stem cells expressing green fluorescent protein (GFP-mMSCs)
were isolated from 4/6-week-old GFP mice and transfected with a recombinant retrovirus-murine stem cell
virus (MSCV) encoding human insulin gene, thus constructing the GFP-mMSCs-MCV-insulin. 16 C57BL/6J
mice were injected with streptozotocin so as to establish models of type 1 diabetes and then randomly divided
into 4 equal groups: Group A, undergoing injection into the liver with GFP-mMSC-MCV-insulin 1 week after the
establishment of the model, Group B, undergoing intrahepatic transplantation of the GFP-mMSCs transfected
with blank vector, Group C, undergoing intrahepatic transplantation of untransfected GFP-mMSCs, and
Group D, undergoing intrahepatic transplantation of phosphate-buffered saline (PBS). Another 4 normal mice
were used as controls and underwent intrahepatic transplantation of PBS too. After the transplantation the
blood glucose, serum insulin, and body weight were detected everyday. 6 weeks later immunohistochemistry
was used to detect the expression of human insulin in the mice liver tissues.
RESULTS: The body weight of Group A increased by 6% within 6 weeks after treatment, and the average
blood glucose level 7 d and 42 d after transplantation were (10.4 +/- 2.8) mmol/L and (6.5 +/- 0.9) mmol/L
respectively, both significantly lower than those of Group D [(26.8 +/- 2.5) mmol/L and (25.4 +/- 4.1) mmol/L
respectively, both P < 0.05]. Immunohistochemistry showed secretion of human insulin in serum and liver.
CONCLUSION: The clinical manifestations of diabetes can be relieved effectively by intrahepatic
transplantation of mMSCs expressing human insulin gene. This study implies a novel approach of gene
therapy for type 1 diabetes.
Treatment of type 1 diabetes by transplantation of bone-derived mesenchymal
stem cells expressing human insulin gene: experiment with mice.
[Article in Chinese] Xu J, Zhu MY, LuYH, LuY, Wang ZW.
Source: Department of General Surgery,Affiliated Hospital of Nantong University, Nantong 226001, China.
Zhonghua Yi Xue Za Zhi. 2007 Sep 25;87(36):2557-60.
MesenchymalStemCellsforType1
DiabetesTreatment
28
Immunomodulation by Mesenchymal Stem Cells
A Potential Therapeutic Strategy for Type 1 Diabetes
Mesenchymal stem cells (MSCs) are pluripotent stromal cells that have the potential to give rise to cells of
diverse lineages. Interestingly, MSCs can be found in virtually all postnatal tissues. The main criteria currently
used to characterize and identify these cells are the capacity for self-renewal and differentiation into tissues of
mesodermal origin, combined with a lack in expression of certain hematopoietic molecules. Because of their
developmental plasticity, the notion of MSC-based therapeutic intervention has become an emerging
strategy for the replacement of injured tissues. MSCs have also been noted to possess the ability to impart
profound immunomodulatory effects in vivo. Indeed, some of the initial observations regarding MSC
protection from tissue injury once thought mediated by tissue regeneration may, in reality, result from
immunomodulation. Whereas the exact mechanisms underlying the immunomodulatory functions of MSC
remain largely unknown, these cells have been exploited in a variety of clinical trials aimed at reducing the
burden of immunemediated disease. This article focuses on recent advances that have broadened our
understanding of the immunomodulatory properties of MSC and provides insight as to their potential for
clinical use as a cell-based therapy for immune-mediated disorders and, in particular, type 1 diabetes.
Diabetes 57:1759–1767, 2008
RezaAbdi,1 Paolo Fiorina,1,2 Chaker N.Adra,1,3 MarkAtkinson,4 and Mohamed H. Sayegh1,3
From the 1Transplantation Research Center, Renal Division, Brigham and Women's Hospital and Children's Hospital Boston,
Harvard Medical School, Boston, Massachusetts; the 2Department of Medicine, San Raffaele Scientific Institute, Milan, Italy; the
3Stem Cell Therapy Program, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia; and the 4Department of
Pathology, Immunology and Laboratory Medicine, University of Florida College of Medicine, Gainesville, Florida.
Corresponding author: RezaAbdi, rabdi@rics.bwh.harvard. DIABETES, VOL. 57, JULY2008
MesenchymalStemCellsforType1
DiabetesTreatment
BMC Med. 2012 Jan 10;10:3. doi: 10.1186/1741-7015-10-3.
29
16. 17
ABSTRACT
BACKGROUND: Inability to control autoimmunity is the primary barrier to developing a cure for type 1
diabetes (T1D). Evidence that human cord blood-derived multipotent stem cells (CB-SCs) can control
autoimmune responses by altering regulatory T cells (Tregs) and human islet â cell-specific T cell clones
offers promise for a new approach to overcome the autoimmunity underlying T1D.
METHODS: We developed a procedure for Stem Cell Educator therapy in which a patient's blood is circulated
through a closed-loop system that separates lymphocytes from the whole blood and briefly co-cultures them
with adherent CB-SCs before returning them to the patient's circulation. In an open-label, phase1/phase 2
study, patients (n=15) with T1D received one treatment with the Stem Cell Educator. Median age was 29 years
(range: 15 to 41), and median diabetic history was 8 years (range: 1 to 21).
RESULTS: Stem Cell Educator therapy was well tolerated in all participants with minimal pain from two
venipunctures and no adverse events. StemCell Educator therapy can markedly improve C-peptide levels,
reduce the median glycated hemoglobin A1C (HbA1C) values, and decrease the median daily dose of insulin
in patients with some residual â cell function (n=6) and patients with no residual pancreatic islet â cell function
(n=6).Treatment also produced an increase in basal and glucose-stimulated C-peptide levels through 40
weeks. However, participants in the Control Group (n=3) did not exhibit significant change at any follow-up.
Individuals who received Stem Cell Educator therapy exhibited increased expression of co-stimulating
molecules (specifically, CD28 and ICOS), increases in the number of CD4+CD25+Foxp3+Tregs, and
restoration of Th1/Th2/Th3 cytokine balance.
CONCLUSIONS: Stem Cell Educator therapy is safe, and in individuals with moderate or severe T1D, a single
treatment produces lasting improvement in metabolic control. Initial results indicate Stem Cell Educator
therapy reverses autoimmunity and promotes regeneration of islet âcells. Successful immune modulation by
CB-SCs and the resulting clinical improvement in patient status may have important implications for other
autoimmune and inflammation-related diseases without the safety and ethical concerns associated with
conventional stem cell-based approaches.
Reversal of type 1 diabetes via islet â cell regeneration following immune
modulation by cord blood-derived multipotent stem cells.
ZhaoY, Jiang Z, ZhaoT,Ye M, Hu C,Yin Z, Li H, ZhangY, DiaoY, LiY, ChenY, Sun X, Fisk MB, Skidgel R, Holterman M, Prabhakar B, MazzoneT.
Source: Section of Endocrinology, Diabetes & Metabolism, Department of Medicine, University of Illinois at Chicago, 1819 West Polk Street,
Chicago, IL60612, USA. yongzhao@uic.edu
MesenchymalStemCellsforType1DiabetesTreatment
30
ABSTRACT
The post-natal dental pulp tissue contains a population of multipotent mesenchymal progenitor cells known
as dental pulp stromal/stem cells (DPSCs), with high proliferative potential for self-renewal. In this
investigation, we explored the potential of DPSCs to differentiate into pancreatic cell lineage resembling islet-
like cell aggregates (ICAs). We isolated, propagated, and characterized DPSCs and demonstrated that these
could be differentiated into adipogenic, chondrogenic, and osteogenic lineage upon exposure to an
appropriate cocktail of differentiating agents. Using a three-step protocol reported previously by our group,
we succeeded in obtaining ICAs from DPSCs. The identity of ICAs was confirmed as islets by dithiozone-
positive staining, as well as by expression of C-peptide, Pdx-1, Pax4, Pax6, Ngn3, and Isl-1. There were
several-fold up-regulations of these transcription factors proportional to days of differentiation as compared
with undifferentiated DPSCs. Day 10 ICAs released insulin and C-peptide in a glucose-dependent manner,
exhibiting in vitro functionality. Our results demonstrated for the first time that DPSCs could be differentiated
into pancreatic cell lineage and offer an unconventional and non-controversial source of human tissue that
could be used for autologous stem cell therapy in diabetes.
Received August 23, 2010. Revision received December 1, 2010. Accepted December 1, 2010.
Differentiation of Dental Pulp Stem Cells into Islet-likeAggregates
V. Govindasamy1, V.S. Ronald2, A.N. Abdullah2, K.R. Ganesan Nathan1, Z.A.C. Ab. Aziz3, M. Abdullah3, S. Musa2, N.H.
Abu Kasim3#, and R. R. Bhonde1*
1
Stempeutics Research Malaysia Sdn Bhd, (773817-K), Lot G-E-2A, Enterprise 4, Technology Park Malaysia, Bukit Jalil, 57000
2
Kuala Lumpur, Malaysia Department of Children's Dentistry and Orthodontics, Faculty of Dentistry, University of Malaya, Kuala
3
Lumpur, Malaysia Department of Conservative Dentistry, Faculty of Dentistry, University of Malaya, 50603 Kuala Lumpur, Malaysia
* #
rrbhonde@stempeutics.com.my nhayaty@um.edu.my
Pleasemailthebulletpoint
31
17. 18
Abstract
Long-term studies strongly suggest that tight control of blood glucose can prevent the development and
retard the progression of chronic complications of type 1diabetes mellitus. In contrast to conventional insulin
treatment, replacement of a patient's islets of Langerhans either by pancreas organ transplantation of by
isolated islet transplantation is the only treatment to achieve a constant normoglycemic state and avoiding
hypoglycemic episodes, a typical adverse event of multiple daily insulin injections. However, the expense of
this benefit is still the need for immunosuppressive treatment of the recipient with all its potential risks. Islet cell
transplantation offers the advantage of being performed as a minimally invasive procedure, in which islets can
be perfused percutaneously into the liver via the portal vein. As of June 2003, 705 pancreatic islet transplants
worldwide have been reported to the International Islet Transplant Registry (ITR) at our Third Medical
Department, University of Giessen/Germany. Data analysis shows at 1year after adult islet transplantation a
patient survival rate of 97% a functioning islet graft in 54% of the cases, whereas insulin independence was
meanwhile achieved in 20% of the cases. However, using a novel protocol established by the Edmonton
Center/Canada, the insulin independence rates have improved significantly reaching meanwhile a 50-80%
level. Finally, the concept of islet cell or stem cell transplantation is most attractive since it offers many
perspectives: islet cell availability could become unlimited and islet or stem cells my be transplanted without
life-long immunosuppressive treatment of the recipient, just to mention 2 of them
Pancreatic islet and stem cell transplantation: new strategies in cell
therapy of diabetes mellitus.
Bretzel RG, Eckhard M, Brendel MD.Third Medical Department and Polyclinic, University Hospital Giessen, Giessen, Germany.
reinhard.bretzel@innere.med.uni-giessen.de
PMID:15238879 [PubMed - indexed for MEDLINE]
StemCellsforDiabetesCure
32
ABSTRACT
BACKGROUND: Cerebral palsy is currently one of the major diseases that cause severe paralysis of the nervous
system in children; approximately 9–30% of cerebral palsy patients are also visually impaired, for which no
effective treatment is available. Bone marrow mesenchymal stem cells (BMSCs) have very strong self-renewal,
proliferation, and pluripotent differentiation potentials. Therefore, autologous BMSC transplantation has become
a novel method for treating cerebral palsy.
METHODS: An 11-year-old boy had a clear history of dystocia and asphyxia after birth; at the age of 6 months, the
family members observed that his gaze roamed and noted that he displayed a lack of attention. A brain MRI
examination at the age of 7 years showed that the child had cerebral palsy with visual impairment (i.e., posterior
visual pathway injury). The patient was hospitalized for 20 days and was given four infusions of
intravenousautologous BMSCs. Before transplantation and 1, 6, and 12 months after transplantation, a visual
evoked potential test, an electrocardiogram, routine blood tests, and liver and kidney function tests were
performed.
RESULTS: The patient did not have any adverse reactions during hospitalization or postoperative follow-up. After
discharge, the patient could walk more smoothly than he could before transplantation; furthermore, his vision
significantly improved 6 months after transplantation, which was also supported by the electrophysiological
examinations.
CONCLUSIONS: The clinical application of BMSCs is effective for improving vision in a patient with cerebral palsy
combined with visual impairment.
Treatment of one case of cerebral palsy combined with posterior visual pathway
injury using autologous bone marrow Mesenchymal stem cells
Li et al. Journal ofTranslational Medicine 2012, 10:100 http://www.translational-medicine.com/content/10/1/100
Min Li1,AixueYu1, Fangfang Zhang1, GuangHui Dai1, Hongbin Cheng1, Xiaodong Wang1 andYihuaAn1,2*
StemCellTherapyinCerebralPalsyTreatment
34
19. 09
MesenchymalStemCellsinOsteoarthitis
BACKGROUND: Osteoarthritis (OA) is a progressive disorder of the joints caused by gradual loss of articular
cartilage, which naturally possesses a limited regenerative capacity. In the present study, the potential of intra-
articular injection of mesenchymal stem cells (MSCs) has been evaluated in six osteoarthritic patients.
METHODS: Six female volunteers, average age of 54.56 years, with radiologic evidence of knee OA that
required joint replacement surgery were selected for this study. About 50 ml bone marrow was aspirated from
each patient and taken to the cell laboratory, where MSCs were isolated and characterized in terms of some
surface markers. About 20-24 × 10(6) passaged-2 cells were prepared and tested for microbial contamination
prior to intra-articular injection.
RESULTS: During a one-year follow-up period, we found no local or systemic adverse events. All patients were
partly satisfied with the results of the study. Pain, functional status of the knee, and walking distance tended to
be improved up to six months post-injection, after which pain appeared to be slightly increased and patients'
walking abilities slightly decreased. Comparison of magnetic resonance images (MRI) at baseline and six
months post-stem cell injection displayed an increase in cartilage thickness, extension of the repair tissue over
the subchondral bone and a considerable decrease in the size of edematous subchondral patches in three out
of six patients.
CONCLUSION: The results indicated satisfactory effects of intra-articular injection of MSCs in patients with
knee OA.
Intra-articular Injection of Autologous Mesenchymal Stem Cells in Six Patients
with Knee Osteoarthritis
Archives of Iranian Medicine, Volume 15, Number 7, July 2012
Mohsen Emadedin MD1, Naser Aghdami MD PhD1,2, Leila Taghiyar MSc2, Roghayeh Fazeli MD1, Reza Moghadasali MSc1,
Shahrbanoo Jahangir MSc2, Reza Farjad MD3
1Department of Regenerative Biomedicine and Cell Therapy, Cell Science Research Center, Royan Institute for Stem Cell Biology
andTechnology,ACECR,Tehran, Iran,2Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan
Institute for Stem Cell Biology andTechnology,ACECR,Tehran, Iran,
RolepfMesenchymalStemCellsin
Arthitistreatment
Mesenchymal stem cells in arthritic diseases
Mesenchymal stem cells (MSCs), the nonhematopoietic progenitor cells found in various adult tissues, are
characterized by their ease of isolation and their rapid growth in vitro while maintaining their differentiation
potential, allowing for extensive culture expansion to obtain large quantities suitable for therapeutic use. These
properties make MSCs an ideal candidate cell type as building blocks for tissue engineering efforts to
regenerate replacement tissues and repair damaged structures as encountered in various arthritic conditions.
Osteoarthritis (OA) is the most common arthritic condition and, like rheumatoid arthritis (RA), presents an
inflammatory environment with immunological involvement and this has been an enduring obstacle that can
potentially limit the use of cartilage tissue engineering. Recent advances in our understanding of the functions
of MSCs have shown that MSCs also possess potent immunosuppression and anti-inflammation effects. In
addition, through secretion of various soluble factors, MSCs can influence the local tissue environment and
exert protective effects with an end result of effectively stimulating regeneration in situ. This function of MSCs
can be exploited for their therapeutic application in degenerative joint diseases such as RA and OA. This
review surveys the advances made in the past decade which have led to our current understanding of stem cell
biology as relevant to diseases of the joint.
Faye H Chen and Rocky STuanArthritis Research &Therapy Vol 10 No 5
Cartilage Biology and Orthopaedics Branch,
National Institute ofArthritis, and Musculoskeletal and Skin Diseases, National Institutes of Health,
Department of Health and Human Services, Building 50, 50 South Dr., Bethesda, MD 20892, USA
13
14
20. 21
Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-
versus-host disease: a phase II study.
ABSTRACT
BACKGROUND: Severe graft-versus-host disease (GVHD) is a life-threatening complication after allogeneic
transplantation with haemopoietic stemcells. Mesenchymal stem cells modulate immune responses in vitro and
in vivo. We aimed to assess whether mesenchymal stem cells could ameliorate GVHD after haemopoietic-stem-
cell transplantation.
METHODS: Patients with steroid-resistant, severe, acute GVHD were treated with mesenchymal stem cells,
derived with the European Group for Blood and Marrow Transplantation ex-vivo expansion procedure, in a
multicentre, phase II experimental study. We recorded response, transplantation-related deaths, and other
adverse events for up to 60 months' follow-up from infusion of the cells.
FINDINGS: Between October, 2001, and January, 2007, 55 patients were treated. The median dose of bone-
marrow derived mesenchymal stem cellswas 1.4x10(6) (min-max range 0.4-9x10(6)) cells per kg bodyweight. 27
patients received one dose, 22 received two doses, and six three to five doses of cells obtained from HLA-identical
sibling donors (n=5), haploidentical donors (n=18), and third-party HLA-mismatched donors (n=69). 30 patients
had a complete response and nine showed improvement. No patients had side-effects during or immediately
after infusions of mesenchymal stem cells. Response rate was not related to donor HLA-match. Three patients
had recurrent malignant disease and one developed de-novo acute myeloid leukaemia of recipient origin.
Complete responders had lower transplantation-related mortality 1 year after infusion than did patients with
partial or no response (11 [37%] of 30 vs 18 [72%] of 25; p=0.002) and higher overall survival 2 years after
haemopoietic-stem-cell transplantation (16 [53%] of 30 vs four [16%] of 25; p=0.018).
INTERPRETATION: Infusion of mesenchymal stem cells expanded in vitro, irrespective of the donor, might be an
effective therapy for patients with steroid-resistant, acute GVHD.
Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM,
BacigalupoA, Fibbe W,Ringdén O; Developmental Committee of the European Group for Blood and MarrowTransplantation.
Source: Haematology Centre and Centre ofAllogeneic Stem Cell Transplantation, Division of Clinical Immunology, Karolinska University
Hospital, Huddinge, Stockholm, Sweden. katarina.leblanc@ki.se
Lancet. 2008 May 10;371(9624):1579-86. doi: 10.1016/S0140-6736(08)60690-X.
MesenchymalStemCellsfortreatmentofacutegraft-versus-
hostdisease
ABSTRACT
INTRODUCTION: Stem cells from human exfoliated deciduous teeth (SHED) have been identified as a
population of postnatal stem cells capable of differentiating into osteogenic and odontogenic cells, adipogenic
cells, and neural cells. Herein we have characterized mesenchymal stem cell properties of SHED in comparison
to human bone marrow mesenchymal stem cells (BMMSCs).
METHODS: We used in vitro stem cell analysis approaches, including flow cytometry, inductive differentiation,
telomerase activity, and Western blot analysis to assess multipotent differentiation of SHED and in vivo
implantation to assess tissue regeneration of SHED. In addition, we utilized systemic SHED transplantation to
treat systemic lupus erythematosus (SLE)-like MRL/lpr mice.
RESULTS: We found that SHED are capable of differentiating into osteogenic and adipogenic cells, expressing
mesenchymal surface molecules (STRO-1, CD146, SSEA4, CD73, CD105, and CD166), and activating multiple
signaling pathways, including TGFâ, ERK, Akt, Wnt, and PDGF. Recently, BMMSCs were shown to possess an
immunomodulatory function that leads to successful therapies for immune diseases. We examined the
immunomodulatory properties of SHED in comparison to BMMSCs and found that SHED had significant effects
on inhibiting T helper 17 (Th17) cells in vitro. Moreover, we found that SHED transplantation is capable of
effectively reversing SLE-associated disorders in MRL/lpr mice. At the cellular level, SHED transplantation
elevated the ratio of regulatory T cells (Tregs) via Th17 cells.
CONCLUSIONS: These data suggest that SHED are an accessible and feasible mesenchymal stem cell source
for treating immune disorders like SLE.
Immunomodulatory properties of stem cells from human exfoliated deciduous
teeth
TakayoshiYamaza1,2,#,Akiyama Kentaro1, #, Chider Chen1,Yi Liu1,Yufang Shi3, Stan Gronthos4, Songlin Wang5, Songtao Shi*
Yamaza et al. Stem Cell Research & Therapy 2010, 1:5 http://stemcellres.com/content/1/1/5
Immunomodulatorypropertiesof
DentalStemCells
38
39
21. 22
MesenchymalStemCellsLowerIncidenceofAcuteRejectioninKidneyTransplantCases
Induction therapy with autologous mesenchymal stem cells in living-related
kidney transplants: a randomized controlled trial.
ABSTRACT
CONTEXT: Antibody-based induction therapy plus calcineurin inhibitors (CNIs) reduce acute rejection rates in
kidney recipients; however, opportunistic infections and toxic CNI effects remain challenging. Reportedly,
mesenchymal stem cells (MSCs) have successfully treated graft-vs-host disease.
OBJECTIVE: To assess autologous MSCs as replacement of antibody induction for patients with end-stage renal
disease who undergo ABO-compatible, cross-match-negative kidney transplants from a living-related donor.
DESIGN, SETTING, AND PATIENTS: One hundred fifty-nine patients were enrolled in this single-site,
prospective, open-label, randomized study from February 2008-May 2009, when recruitment was completed.
INTERVENTION: Patients were inoculated with marrow-derived autologous MSC (1-2 x 10(6)/kg) at kidney
reperfusion and two weeks later. Fifty-three patients received standard-dose and 52 patients received low-dose
CNIs (80% of standard); 51 patients in the control group received anti-IL-2 receptor antibody plus standard-dose
CNIs.
MAIN OUTCOME MEASURES: The primary measure was 1-year incidence of acute rejection and renal function
(estimated glomerular filtration rate [eGFR]); the secondary measure was patient and graft survival and incidence
of adverse events.
RESULTS: Patient and graft survival at 13 to 30 months was similar in all groups. After 6 months, 4 of 53 patients
(7.5%) in the autologous MSC plus standard-dose CNI group (95% CI, 0.4%-14.7%; P = .04) and 4 of 52 patients
(7.7%) in the low-dose group (95% CI, 0.5%-14.9%; P = .046) compared with 11 of 51 controls (21.6%; 95% CI,
10.5%-32.6%) had biopsy-confirmed acute rejection. None of the patients in either autologous MSC group had
glucorticoid-resistant rejection, whereas 4 patients (7.8%) in the control group did (95% CI, 0.6%-15.1%; overall P
= .02). Renal function recovered faster among both MSC groups showing increased eGFR levels during the first
month after surgery than the control group. Patients receiving standard-dose CNI had a mean difference of 6.2
mL/min per 1.73 m(2) (95% CI, 0.4-11.9; P=.04) and those in the low-dose CNI of 10.0 mL/min per 1.73 m(2) (95%
CI, 3.8-16.2; P=.002). Also, during the 1-year follow-up, combined analysis of MSC-treated groups revealed
significantly decreased risk of opportunistic infections than the control group (hazard ratio, 0.42; 95% CI, 0.20-
0.85, P=.02)
CONCLUSION: Among patients undergoing renal transplant, the use of autologous MSCs compared with anti-IL-
2 receptor antibody induction therapy resulted in lower incidence of acute rejection, decreased risk of
opportunistic infection, and better estimated renal function at 1 year.
Tan J, Wu W, Xu X, Liao L, Zheng F, Messinger S, Sun X, Chen J,Yang S, Cai J, Gao X, PileggiA, Ricordi C.
Source: Organ Transplant Institute, Fuzhou General Hospital, Xiamen University and Fujian Key Laboratory of Transplant Biology,
Fuzhou, China. tanjm156@yahoo.com.cn
JAMA. 2012 Mar 21;307(11):1169-77. doi: 10.1001/jama.2012.316.
40
22. 23
Acute-on-chronic liver failure (ACLF) is a severe, life-threatening complication, and new and efficient therapeutic
strategies for liver failure are urgently needed. Mesenchymal stem cell (MSC) transfusions have been shown to
reverse fulminant hepatic failure in mice and to improve liver function in patients with end-stage liver diseases. We
assessed the safety and initial efficacy of umbilical cordderived MSC (UC-MSC) transfusions for ACLF patients
associated with hepatitis B virus (HBV) infection.A total of 43 ACLF patients were enrolled for this open-labeled
and controlled study; 24 patients were treated with UC-MSCs, and 19 patients were treated with saline as controls.
UC-MSC therapy was given three times at 4-week intervals. The liver function, adverse events, and survival rates
were evaluated during the 48-week or 72-week follow-up period. No significant side effects were observed during
the trial. The UC-MSC transfusions significantly increased the survival rates in ACLF patients; reduced the model
for end-stage liver disease scores; increased serum albumin, cholinesterase, and prothrombin activity; and
increased platelet counts. Serum total bilirubin and alanine aminotransferase levels were significantly decreased
after the UC-MSC transfusions. UC-MSC transfusions are safe in the clinic and may serve as a novel therapeutic
approach for HBV-associated ACLF patients.
Human Mesenchymal Stem Cell Transfusion Is Safe and Improves Liver Function
inAcute-on-Chronic Liver Failure Patients
MING SHI,a,b* ZHENG ZHANG,a* RUONAN XU,a* HU LIN,a JUNLIANG FU,a ZHENGSHENG ZOU,a
AIMIN ZHANG,a JIANFEI SHI,a LIMING CHEN,a SALV,aWEIPING HE,a HUAGENG,a LEI JIN,a
ZHENWEN LIU,b FU-SHENGWANGa
Key Words. Clinical trials Stem cell transplantation Umbilical cord Liver
aResearch Center for BiologicalTherapy, Institute ofTranslational Hepatology,
and bResearch Center for LiverTransplantation, Beijing 302 Hospital, Beijing, China
MesenchymalStemCellsforLiverFailure
Treatment
High-purity hepatic differentiated from dental pulp stem cells in serum-free
medium
INTRODUCTION: We have previously differentiated hepatocyte like cells from deciduoud tooth pulp stem and
extracted third molar pulp stem cells with a protocol that used fetal bovine serum, but it showed high
contaminations of nondifferentiated cells. Both the lower purity of hepatically differentiated cells and usage of
serum are obstacles for applications of cell therapy or regenerative medicine. Objective of this study was to
investigate the capacity for and purity of hepatocyte-like differentiation of CD 117-positive dental pulp stem cells
without serum.
METHODS: Mesenchymal cells from human deciduous and extracted third molar pulp were isolated and
expanded in vitro. We separated D117-position cells by using a magnetic-activated cell sorter. The cells were
characterized immunofluorescently by using known stem cell markers. For hepatic differentiation, the media were
supplemented with hepatic growth factor, insulin transferring-selenium-x, dexamethasone, and oncostatin M.
Expression of hepatic markers alpha fetoprotein, albumin, hepatic nuclear factor-4 alpha, insulin-like growth
factor-1, and carbamoyl phosphate synthetase was examined immunoflurescently after differentiation. The
amount of differentiated cells was assessed by using flow cytometry. Glycogen storage and area concentration in
the medium were defined.
RESULTS: Both cell cultures demonstrated a number of cells positive for all tested hepatic markers after
differentiation,ie, albumin-positive cells were almost 90% of differentiated deciduous pulp cells. The
concentration of urea in the media increased significantly after differentiation. Significant amount of cytoplasmic
glycogen storage was found in the cells.
CONCLUSIONS: Without serum both cell types differentiated into high-purity hepatocyte-like cells. These cells
offer a source for hepatocypte lineage differentiation for transplantation in the future.
J Endod 2012 Apr;38(4):475-80. Epub 2012 Jan28
DentalStemCellsConverttoHepaticCells
41
42
23. Contact us for information or request a visit:
Follow us on: facebook.com/stemadebiotechf twitter.com/stemadebiotech
Stemade Biotech Pvt. Ltd.
Andheri-Kurla Road, Andheri (East), Mumbai - 400059, India
401-404 Dynasty Business Park, B-wing, Level 4, Kanakia Spaces,